<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<!--Generated by IRIS Proton Version 2.0.4.1-->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:vrx="http://www.valeant.com/20120930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:schemaRef xlink:type="simple" xlink:href="vrx-20120930.xsd" />
  <xbrli:context id="I2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3SO">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeveranceAndRelatedBenefitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:SeveranceAndRelatedBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ContractTerminationFacilityClosureAndOtherCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ContractTerminationFacilityClosureAndOtherCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_ContractTerminationFacilityClosureAndOtherCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ContractTerminationFacilityClosureAndOtherCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_SeveranceAndRelatedBenefitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:SeveranceAndRelatedBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_InovaPharmaceuticalsMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_InovaPharmaceuticalsMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1221_InovaPharmaceuticalsMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1221_InovaPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1221_InovaPharmaceuticalsMember_ProductBrandsMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_InovaPharmaceuticalsMember_ScenarioAdjustmentMember_ProductBrandsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_InovaPharmaceuticalsMember_ProductBrandsMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1221_InovaPharmaceuticalsMember_CorporateBrandsMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:CorporateBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_InovaPharmaceuticalsMember_CorporateBrandsMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:CorporateBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1221_InovaPharmaceuticalsMember_CanadaAndAustraliaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:CanadaAndAustraliaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1221_InovaPharmaceuticalsMember_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1216_DermikMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1216_DermikMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1216_ProductBrandsMember_DermikMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1216_ContractualRightsMember_DermikMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1216_ManufacturingAgreementsMember_DermikMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ManufacturingAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1212_OrthoDermatologicsAssetsMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OrthoDermatologicsAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1017_AfexaLifeSciencesIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-10-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_AfexaLifeSciencesIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_DermikMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ProductBrandsMember_DermikMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ContractualRightsMember_DermikMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ManufacturingAgreementsMember_DermikMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ManufacturingAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_OrthoDermatologicsAssetsMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OrthoDermatologicsAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_CorporateBrandsMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:CorporateBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_CorporateBrandsMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:CorporateBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_CorporateBrandsMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:CorporateBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_PartnerRelationshipsMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:PartnerRelationshipsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_PartnerRelationshipsMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:PartnerRelationshipsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ProductBrandsMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ProductBrandsMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ProbioticaLaboratoriosLtdaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:ProbioticaLaboratoriosLtdaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ProbioticaLaboratoriosLtdaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:ProbioticaLaboratoriosLtdaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_InovaPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_DermikMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_OrthoDermatologicsAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OrthoDermatologicsAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1017_AfexaLifeSciencesIncMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-10-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_AfexaLifeSciencesIncMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_AfexaLifeSciencesIncMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1017_ProductBrandsMember_AfexaLifeSciencesIncMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-10-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q4_M1017_PatentedTechnologyMember_AfexaLifeSciencesIncMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-10-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ProductBrandsMember_AfexaLifeSciencesIncMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_PatentedTechnologyMember_AfexaLifeSciencesIncMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ProductBrandsMember_AfexaLifeSciencesIncMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_M07_SanitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:SanitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_M0915_SanitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:SanitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-09-14</xbrli:startDate>
      <xbrli:endDate>2011-09-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_M0819_SanitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:SanitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-08-18</xbrli:startDate>
      <xbrli:endDate>2011-08-19</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_M0819_SanitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:SanitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-08-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_M0915_SanitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:SanitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_M0922_SanitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:SanitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_M0731_SanitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:SanitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SanitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:SanitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_SanitasMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:SanitasMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q4_ClindamycinAndBenzoylPeroxideGelMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SignificantAcquisitionsAndDisposalsByTransactionAxis">vrx:ClindamycinAndBenzoylPeroxideGelMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-10-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q4_FluorouracilCreamMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SignificantAcquisitionsAndDisposalsByTransactionAxis">vrx:FluorouracilCreamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-10-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_ClindamycinAndBenzoylPeroxideGelAndFluorouracilCreamMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SignificantAcquisitionsAndDisposalsByTransactionAxis">vrx:ClindamycinAndBenzoylPeroxideGelAndFluorouracilCreamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ZoviraxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SignificantAcquisitionsAndDisposalsByTransactionAxis">vrx:ZoviraxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q1_ClodermMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SignificantAcquisitionsAndDisposalsByTransactionAxis">vrx:ClodermMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ClindamycinAndBenzoylPeroxideGelMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SignificantAcquisitionsAndDisposalsByTransactionAxis">vrx:ClindamycinAndBenzoylPeroxideGelMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ZoviraxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SignificantAcquisitionsAndDisposalsByTransactionAxis">vrx:ZoviraxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q1_M0325_ZoviraxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SignificantAcquisitionsAndDisposalsByTransactionAxis">vrx:ZoviraxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_FluorouracilCreamMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SignificantAcquisitionsAndDisposalsByTransactionAxis">vrx:FluorouracilCreamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_GlaxoSmithKlineMember_PotigaMember_CollaborativeArrangementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">vrx:GlaxoSmithKlineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:PotigaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0430_GlaxoSmithKlineMember_PotigaMember_CollaborativeArrangementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">vrx:GlaxoSmithKlineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:PotigaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q2_M0531_GlaxoSmithKlineMember_TrobaltMember_CollaborativeArrangementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">vrx:GlaxoSmithKlineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:TrobaltMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_SeveranceAndRelatedBenefitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:SeveranceAndRelatedBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ShareBasedCompensationRestructuringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ShareBasedCompensationRestructuringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_SeveranceAndRelatedBenefitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:SeveranceAndRelatedBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_ContractTerminationFacilityClosureAndOtherCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ContractTerminationFacilityClosureAndOtherCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ContractTerminationFacilityClosureAndOtherCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ContractTerminationFacilityClosureAndOtherCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_SeveranceAndRelatedBenefitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:SeveranceAndRelatedBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_ContractTerminationFacilityClosureAndOtherCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ContractTerminationFacilityClosureAndOtherCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_SeveranceAndRelatedBenefitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:SeveranceAndRelatedBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_ContractTerminationFacilityClosureAndOtherCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ContractTerminationFacilityClosureAndOtherCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_SeveranceAndRelatedBenefitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:SeveranceAndRelatedBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_InProcessResearchAndDevelopmentTerminationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:InProcessResearchAndDevelopmentTerminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_ContractTerminationFacilityClosureAndOtherCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ContractTerminationFacilityClosureAndOtherCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_SeveranceAndRelatedBenefitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:SeveranceAndRelatedBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_ShareBasedCompensationRestructuringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ShareBasedCompensationRestructuringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_ContractTerminationFacilityClosureAndOtherCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ContractTerminationFacilityClosureAndOtherCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_SeveranceAndRelatedBenefitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:SeveranceAndRelatedBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_ContractTerminationFacilityClosureAndOtherCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ContractTerminationFacilityClosureAndOtherCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_SeveranceAndRelatedBenefitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:SeveranceAndRelatedBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_ContractTerminationFacilityClosureAndOtherCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ContractTerminationFacilityClosureAndOtherCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010_ShareBasedCompensationRestructuringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ShareBasedCompensationRestructuringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_ShareBasedCompensationRestructuringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ShareBasedCompensationRestructuringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ContractTerminationFacilityClosureAndOtherCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:ContractTerminationFacilityClosureAndOtherCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_OperatingLeaseObligationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">vrx:OperatingLeaseObligationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CarryingReportedAmountFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByBalanceSheetGroupingDisclosureItemAmountsAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByBalanceSheetGroupingDisclosureItemAmountsAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_CarryingReportedAmountFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByBalanceSheetGroupingDisclosureItemAmountsAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByBalanceSheetGroupingDisclosureItemAmountsAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CorporateBondSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_EquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CarryingReportedAmountFairValueDisclosureMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByBalanceSheetGroupingDisclosureItemAmountsAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_CarryingReportedAmountFairValueDisclosureMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByBalanceSheetGroupingDisclosureItemAmountsAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CarryingReportedAmountFairValueDisclosureMember_FairValueMeasurementsRecurringMember_EquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByBalanceSheetGroupingDisclosureItemAmountsAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember_EquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CarryingReportedAmountFairValueDisclosureMember_FairValueMeasurementsRecurringMember_CorporateBondSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByBalanceSheetGroupingDisclosureItemAmountsAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember_CorporateBondSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ContingentConsiderationArrangementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vrx:ContingentConsiderationArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ContingentConsiderationArrangementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vrx:ContingentConsiderationArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_M0614_SeniorSecuredTermLoanBFacilityMember_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-06-13</xbrli:startDate>
      <xbrli:endDate>2012-06-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ContingentConsiderationArrangementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vrx:ContingentConsiderationArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ProductBrandsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_TradeNamesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ContractualRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_PartnerRelationshipsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:PartnerRelationshipsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_OutLicensedTechnologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:OutLicensedTechnologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ProductBrandsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_TradeNamesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ContractualRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_PartnerRelationshipsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:PartnerRelationshipsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_OutLicensedTechnologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:OutLicensedTechnologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_USNeurologyAndOtherMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USNeurologyAndOtherMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_USDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CanadaAndAustraliaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:CanadaAndAustraliaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_USNeurologyAndOtherMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USNeurologyAndOtherMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_USDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_CanadaAndAustraliaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:CanadaAndAustraliaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_USDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_CanadaAndAustraliaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:CanadaAndAustraliaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_AfexaLifeSciencesIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_ValueActCapitalMasterFundLPMember_SecuritiesRepurchaseProgramMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrx:ValueActCapitalMasterFundLPMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">vrx:SecuritiesRepurchaseProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_M0313_GerotLannachMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:GerotLannachMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M0709_SeniorSecuredTermLoanBFacilityMember_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-08</xbrli:startDate>
      <xbrli:endDate>2012-07-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_M0201_ProbioticaLaboratoriosLtdaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:ProbioticaLaboratoriosLtdaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_TermLoanAFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:TermLoanAFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_TermLoanBFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:TermLoanBFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeniorNotes6.50PercentDueJuly2016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes6.50PercentDueJuly2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeniorNotes6.75PercentDueOctober2017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes6.75PercentDueOctober2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeniorNotes6.875PercentDueDecember2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes6.875PercentDueDecember2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeniorNotes7.00PercentDueOctober2020Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes7.00PercentDueOctober2020Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeniorNotes6.75PercentDueAugust2021Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes6.75PercentDueAugust2021Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeniorNotes7.25PercentDueJuly2022Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes7.25PercentDueJuly2022Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_TermLoanAFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:TermLoanAFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_SeniorNotes6.50PercentDueJuly2016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes6.50PercentDueJuly2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_SeniorNotes6.75PercentDueOctober2017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes6.75PercentDueOctober2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_SeniorNotes6.875PercentDueDecember2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes6.875PercentDueDecember2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_SeniorNotes7.00PercentDueOctober2020Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes7.00PercentDueOctober2020Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_SeniorNotes6.75PercentDueAugust2021Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes6.75PercentDueAugust2021Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_SeniorNotes7.25PercentDueJuly2022Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes7.25PercentDueJuly2022Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ConvertibleNotesPayable5.375PercentDueAugust2014Member_LTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ConvertibleNotesPayable5.375PercentDueAugust2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_M0213_SeniorSecuredTermCreditFacilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermCreditFacilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0925_BrazilUncommittedLineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:BrazilUncommittedLineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_BrazilUncommittedLineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:BrazilUncommittedLineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_BrazilUncommittedLineOfCreditMember_DebtInstrumentInterbankDepositCertificateRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:BrazilUncommittedLineOfCreditMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentInterbankDepositCertificateRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_BrazilUncommittedLineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:BrazilUncommittedLineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_M0213_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_M0213_SeniorSecuredTermLoanAFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanAFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_M0213_SeniorSecuredTermLoanBFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_SeniorSecuredTermLoanAFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanAFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_SeniorSecuredTermLoanBFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeniorSecuredTermLoanAFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanAFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeniorSecuredTermLoanBFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_RevolvingCreditFacilityAndTermLoanAFacilityMember_DebtInstrumentVariableRateBaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:RevolvingCreditFacilityAndTermLoanAFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentVariableRateBaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_RevolvingCreditFacilityAndTermLoanAFacilityMember_DebtInstrumentVariableRateLIBOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:RevolvingCreditFacilityAndTermLoanAFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentVariableRateLIBOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_SeniorSecuredTermCreditFacilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermCreditFacilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeniorSecuredTermCreditFacilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermCreditFacilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q4_M11_SecuritiesRepurchaseProgramMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">vrx:SecuritiesRepurchaseProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-11-01</xbrli:startDate>
      <xbrli:endDate>2010-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_M08_SecuritiesRepurchaseProgramMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">vrx:SecuritiesRepurchaseProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-08-01</xbrli:startDate>
      <xbrli:endDate>2011-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q4_M11_NewSecuritiesRepurchaseProgramMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">vrx:NewSecuritiesRepurchaseProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-11-01</xbrli:startDate>
      <xbrli:endDate>2011-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ConvertibleNotesPayable5.375PercentDueAugust2014Member_NewSecuritiesRepurchaseProgramMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">vrx:NewSecuritiesRepurchaseProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ConvertibleNotesPayable5.375PercentDueAugust2014Member_NewSecuritiesRepurchaseProgramMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">vrx:NewSecuritiesRepurchaseProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_ConvertibleNotesPayable5.375PercentDueAugust2014Member_SecuritiesRepurchaseProgramMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">vrx:SecuritiesRepurchaseProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_ConvertibleNotesPayable5.375PercentDueAugust2014Member_SecuritiesRepurchaseProgramMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">vrx:SecuritiesRepurchaseProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_NewSecuritiesRepurchaseProgramMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">vrx:NewSecuritiesRepurchaseProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q1_M03_ValueActCapitalMasterFundLPMember_SecuritiesRepurchaseProgramMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrx:ValueActCapitalMasterFundLPMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">vrx:SecuritiesRepurchaseProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ContractualRightsMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ValueActCapitalMasterFundLPMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrx:ValueActCapitalMasterFundLPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_SecuritiesRepurchaseProgramMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">vrx:SecuritiesRepurchaseProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_RestructuringChargesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_SellingGeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">vrx:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_CostOfSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_SellingGeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">vrx:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_CostOfSalesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_SellingGeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">vrx:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_RestructuringChargesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q4_M11_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-11-01</xbrli:startDate>
      <xbrli:endDate>2010-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q1_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q1_CostOfSalesMember_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q1_ResearchAndDevelopmentExpenseMember_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q1_SellingGeneralAndAdministrativeExpenseMember_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">vrx:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_TimeBasedRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrx:TimeBasedRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_TimeBasedRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrx:TimeBasedRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_PerformanceBasedRestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrx:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_PerformanceBasedRestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrx:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q1_M0310_PharmaSwissMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:PharmaSwissMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q1_M0228_PharmaSwissMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:PharmaSwissMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q1_PharmaSwissMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:PharmaSwissMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q1_PharmaSwissMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:PharmaSwissMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_PharmaSwissMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:PharmaSwissMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_PharmaSwissMember_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:PharmaSwissMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_EquitySecuritiesMember_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_DebtSecuritiesMember_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_AccumulatedTranslationAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_DebtSecuritiesMember_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_AccumulatedDefinedBenefitPlansAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_AccumulatedTranslationAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_AccumulatedDefinedBenefitPlansAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_ForeignCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q1_M03_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q1_M0314_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2008Q2_M05_BiovailPharmaceuticalsIncMember_WrittenPleaAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vrx:BiovailPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">vrx:WrittenPleaAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2008-05-01</xbrli:startDate>
      <xbrli:endDate>2008-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2008Q2_M05_BiovailPharmaceuticalsIncMember_NonprosecutionAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vrx:BiovailPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">vrx:NonprosecutionAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2008-05-01</xbrli:startDate>
      <xbrli:endDate>2008-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009Q3_M09_BiovailPharmaceuticalsIncMember_CorporateIntegrityAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vrx:BiovailPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">vrx:CorporateIntegrityAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-09-01</xbrli:startDate>
      <xbrli:endDate>2009-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q1_M02_WatsonLaboratoriesIncMember_AplenzinMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vrx:WatsonLaboratoriesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:AplenzinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>
      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_M01_SpearPharmaceuticalsIncMember_FluorouracilTopicalCreamMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vrx:SpearPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:FluorouracilTopicalCreamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_M03_SandozIncMember_BupropionHydrobromideTabletsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vrx:SandozIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:BupropionHydrobromideTabletsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-03-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_WatsonLaboratoriesIncMember_AplenzinMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vrx:WatsonLaboratoriesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:AplenzinMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009Q4_M10_GeneralCivilActionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">vrx:GeneralCivilActionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-10-01</xbrli:startDate>
      <xbrli:endDate>2009-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009Q4_M12_BiovailPharmaceuticalsIncMember_FalseClaimActMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vrx:BiovailPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">vrx:FalseClaimActMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-12-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_USNeurologyAndOtherMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USNeurologyAndOtherMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_USDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_USNeurologyAndOtherMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USNeurologyAndOtherMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_CanadaAndAustraliaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:CanadaAndAustraliaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_USDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_USNeurologyAndOtherMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USNeurologyAndOtherMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_CanadaAndAustraliaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:CanadaAndAustraliaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_UnallocatedAmountToSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:UnallocatedAmountToSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_TotalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:TotalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_TotalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:TotalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_UnallocatedAmountToSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:UnallocatedAmountToSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_M0326_NaturProduktInternationalJSCMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:NaturProduktInternationalJSCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_InovaDermikAndAfexaMember_CanadaAndAustraliaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaDermikAndAfexaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:CanadaAndAustraliaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_InovaDermikAndAfexaMember_CanadaAndAustraliaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaDermikAndAfexaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:CanadaAndAustraliaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_DermikOrthoDermatologistsElidelXereseOraPharmaPedinolUniversityMedicalEyetechMember_USDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikOrthoDermatologistsElidelXereseOraPharmaPedinolUniversityMedicalEyetechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_DermikOrthoDermatologistsElidelXereseOraPharmaPedinolUniversityMedicalEyetechMember_USDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikOrthoDermatologistsElidelXereseOraPharmaPedinolUniversityMedicalEyetechMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_PharmaSwissSanitasiNovaProbioticaAndGerotLannachMember_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:PharmaSwissSanitasiNovaProbioticaAndGerotLannachMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_PharmaSwissSanitasiNovaProbioticaAndGerotLannachMember_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:PharmaSwissSanitasiNovaProbioticaAndGerotLannachMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_UnallocatedAmountToSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:UnallocatedAmountToSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_UnallocatedAmountToSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:UnallocatedAmountToSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_UnallocatedAmountToSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:UnallocatedAmountToSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_UnallocatedAmountToSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:UnallocatedAmountToSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_StockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_USDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_USNeurologyAndOtherMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USNeurologyAndOtherMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_CanadaAndAustraliaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:CanadaAndAustraliaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ForeignCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_GlaxoSmithKlineMember_TrobaltMember_CollaborativeArrangementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">vrx:GlaxoSmithKlineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:TrobaltMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_GlaxoSmithKlineMember_PotigaMember_CollaborativeArrangementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">vrx:GlaxoSmithKlineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:PotigaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q2_GlaxoSmithKlineMember_TrobaltMember_CollaborativeArrangementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">vrx:GlaxoSmithKlineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:TrobaltMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-04-01</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ConvertibleNotesPayable5.375PercentDueAugust2014Member_SRP">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_ConvertibleNotesPayable5.375PercentDueAugust2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q2_M05_ValueActCapitalMasterFundLPMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vrx:ValueActCapitalMasterFundLPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-05-01</xbrli:startDate>
      <xbrli:endDate>2011-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ConvertibleNotesPayable4.00PercentDueNovember2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable4.00PercentDueNovember2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q2_M04_ConvertibleNotesPayable4.00PercentDueNovember2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable4.00PercentDueNovember2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-04-01</xbrli:startDate>
      <xbrli:endDate>2011-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ConvertibleNotesPayable4.00PercentDueNovember2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable4.00PercentDueNovember2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q2_M0420_ConvertibleNotesPayable4.00PercentDueNovember2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable4.00PercentDueNovember2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-04-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q2_ConvertibleNotesPayable4.00PercentDueNovember2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable4.00PercentDueNovember2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-04-01</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q2_M06_ConvertibleNotesPayable4.00PercentDueNovember2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable4.00PercentDueNovember2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-06-01</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_IncrementalTermLoanBMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:IncrementalTermLoanBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_OrthoDermatologicsAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OrthoDermatologicsAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0523_UniversityMedicalPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:UniversityMedicalPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-05-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0502_AtlantisPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AtlantisPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-05-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q2_M04_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-04-01</xbrli:startDate>
      <xbrli:endDate>2011-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ProbioticaLaboratoriosLtdaMember_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:ProbioticaLaboratoriosLtdaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ProbioticaLaboratoriosLtdaMember_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:ProbioticaLaboratoriosLtdaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_M0313_GerotLannachMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:GerotLannachMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-03-12</xbrli:startDate>
      <xbrli:endDate>2012-03-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_GlaxoSmithKlineMember_PotigaMember_CollaborativeArrangementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">vrx:GlaxoSmithKlineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:PotigaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_GlaxoSmithKlineMember_TrobaltMember_CollaborativeArrangementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">vrx:GlaxoSmithKlineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:TrobaltMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeniorSecuredTermLoanBFacilityMember_DebtInstrumentVariableRateBaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentVariableRateBaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeniorSecuredTermLoanBFacilityMember_DebtInstrumentVariableRateLIBOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentVariableRateLIBOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_AntidilutiveCalculationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="vrx:AlternateTypesOfWeightedAverageCommonSharesOutstandingCalculationsAxis">vrx:AntidilutiveCalculationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0618_OraPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_RevolvingCreditFacilityAndTermLoanAFacilityMember_DebtInstrumentVariableRateBaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:RevolvingCreditFacilityAndTermLoanAFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentVariableRateBaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0618_OraPharmaMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_105D_OraPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-06-19</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_AtlantisPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AtlantisPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_InovaPharmaceuticalsMember_CanadaAndAustraliaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:CanadaAndAustraliaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_DermikMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ProductBrandsMember_DermikMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ContractualRightsMember_DermikMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ManufacturingAgreementsMember_DermikMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ManufacturingAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_OrthoDermatologicsAssetsMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OrthoDermatologicsAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_OraPharmaQLTJAndJNorthAmericaUniversityMedicalMember_USDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaQLTJAndJNorthAmericaUniversityMedicalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ConvertibleNotesPayable5.375PercentDueAugust2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0618_OraPharmaMember_ProductBrandsMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0618_OraPharmaMember_CorporateBrandsMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:CorporateBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_AntitrustComplaintMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">vrx:AntitrustComplaintMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_OraPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_M05_PharmaSwissMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:PharmaSwissMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-05-01</xbrli:startDate>
      <xbrli:endDate>2012-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_DermikAndOrthoDermatologicsAssetsMember_USDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikAndOrthoDermatologicsAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_DermikAndOrthoDermatologicsAssetsMember_USDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikAndOrthoDermatologicsAssetsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_GerotLannachAndAtlantisAndProbioticaMember_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:GerotLannachAndAtlantisAndProbioticaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_PharmaSwissSanitasiNovaAndGerotLannachMember_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:PharmaSwissSanitasiNovaAndGerotLannachMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_PharmaSwissSanitasiNovaAndGerotLannachMember_EmergingMarketsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:PharmaSwissSanitasiNovaAndGerotLannachMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:EmergingMarketsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0709_SeniorSecuredTermLoanBFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-07-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_CorporateBrandsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:CorporateBrandsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_PartnerRelationshipsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:PartnerRelationshipsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ProductBrandsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ProductBrandsMember_InovaPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_CorporateBrandsMember_InovaPharmaceuticalsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:CorporateBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ProductBrandsMember_DermikMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ContractualRightsMember_DermikMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ManufacturingAgreementsMember_DermikMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ManufacturingAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:DermikMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ProductBrandsMember_AfexaLifeSciencesIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_PatentedTechnologyMember_AfexaLifeSciencesIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:AfexaLifeSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ProductBrandsMember_OraPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_CorporateBrandsMember_OraPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:CorporateBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_SellingGeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">vrx:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_AccumulatedDefinedBenefitPlansAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_AccumulatedTranslationAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_EquitySecuritiesMember_AccumulatedNetUnrealizedInvestmentGainLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_EquitySecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_ConvertibleNotesPayable4.00PercentDueNovember2013Member_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable4.00PercentDueNovember2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_ConvertibleNotesPayable4.00PercentDueNovember2013Member_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable4.00PercentDueNovember2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_ConvertibleNotesPayable4.00PercentDueNovember2013Member_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable4.00PercentDueNovember2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_ConvertibleNotesPayable4.00PercentDueNovember2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable4.00PercentDueNovember2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_OraPharmaMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_OraPharmaMember_ProductBrandsMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_OraPharmaMember_CorporateBrandsMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:CorporateBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0629_ConvertibleNotesPayable5.375PercentDueAugust2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_ConvertibleNotesPayable5.375PercentDueAugust2014Member_NewSecuritiesRepurchaseProgramMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">vrx:NewSecuritiesRepurchaseProgramMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_ConvertibleNotesPayable5.375PercentDueAugust2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M0709_SeniorSecuredTermLoanBFacilityMember_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-08</xbrli:startDate>
      <xbrli:endDate>2012-07-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3_ConvertibleNotesPayable4.00PercentDueNovember2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable4.00PercentDueNovember2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010_ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_ConvertibleNotesPayable4.00PercentDueNovember2013Member_ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable4.00PercentDueNovember2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3_ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_M06_OraPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-06-17</xbrli:startDate>
      <xbrli:endDate>2012-06-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_RevolvingCreditFacilityAndTermLoanAFacilityMember_DebtInstrumentVariableRateLIBOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:RevolvingCreditFacilityAndTermLoanAFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentVariableRateLIBOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_SeniorSecuredTermLoanBFacilityMember_DebtInstrumentVariableRateLIBOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentVariableRateLIBOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q2_M0614_SeniorSecuredTermLoanBFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_M0614_SeniorSecuredTermLoanBFacilityMember_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-06-13</xbrli:startDate>
      <xbrli:endDate>2012-06-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_OraPharmaMember_ProductBrandsMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:ProductBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_OraPharmaMember_CorporateBrandsMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vrx:CorporateBrandsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0928_JohnsonAndJohnsonNorthAmericaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:JohnsonAndJohnsonNorthAmericaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0924_QLTIncAndQLTOphthalmicsIncMember_US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:QLTIncAndQLTOphthalmicsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0924_QLTIncAndQLTOphthalmicsIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:QLTIncAndQLTOphthalmicsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ContractualRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_RoyaltyAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0928_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ContractualRightsMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_ContractualRightsMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_RoyaltyAgreementsMember_ScenarioActualMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioActualMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_RoyaltyAgreementsMember_ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1002_RepricedTermLoanBFacilityMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:RepricedTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1002_RepricedTermLoanBFacilityMember_SubsequentEventMember_DebtInstrumentVariableRateBaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:RepricedTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentVariableRateBaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1002_RepricedTermLoanBFacilityMember_SubsequentEventMember_DebtInstrumentVariableRateBaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:RepricedTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentVariableRateBaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1002_RepricedTermLoanBFacilityMember_SubsequentEventMember_DebtInstrumentVariableRateLIBOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:RepricedTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentVariableRateLIBOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1002_RepricedTermLoanBFacilityMember_SubsequentEventMember_DebtInstrumentVariableRateLIBOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:RepricedTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentVariableRateLIBOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M0902_MedicisPharmaceuticalCorporationMember_IncrementalTermLoanBMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:IncrementalTermLoanBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-08-31</xbrli:startDate>
      <xbrli:endDate>2012-09-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1002_JohnsonAndJohnsonConsumerCompaniesIncMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:JohnsonAndJohnsonConsumerCompaniesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1002_BMSCollaborationAndOptionAgreementsMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">vrx:BMSCollaborationAndOptionAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0902_MedicisPharmaceuticalCorporationMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0902_MedicisPharmaceuticalCorporationMember_ConvertibleSeniorNotes1.375PercentDue2017Member_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleSeniorNotes1.375PercentDue2017Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0902_MedicisPharmaceuticalCorporationMember_ContingentConvertibleSeniorNotes2.5PercentDue2032Member_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ContingentConvertibleSeniorNotes2.5PercentDue2032Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0902_MedicisPharmaceuticalCorporationMember_ContingentConvertibleSeniorNotes1.5PercentDue2032Member_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ContingentConvertibleSeniorNotes1.5PercentDue2032Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M0902_MedicisPharmaceuticalCorporationMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-08-31</xbrli:startDate>
      <xbrli:endDate>2012-09-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1004_SubsidiariesMember_MedicisPharmaceuticalCorporationMember_SeniorNotes6.375PercentDueOctober2020Member_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes6.375PercentDueOctober2020Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-03</xbrli:startDate>
      <xbrli:endDate>2012-10-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1004_SubsidiariesMember_MedicisPharmaceuticalCorporationMember_SeniorNotes6.375PercentDueOctober2020Member_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes6.375PercentDueOctober2020Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1004_SeniorNotes6.375PercentDueOctober2020Member_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes6.375PercentDueOctober2020Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-03</xbrli:startDate>
      <xbrli:endDate>2012-10-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1004_SeniorNotes6.375PercentDueOctober2020Member_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorNotes6.375PercentDueOctober2020Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0902_MedicisPharmaceuticalCorporationMember_BridgeLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M09_MedicisPharmaceuticalCorporationMember_BridgeLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-09-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ConvertibleNotesPayable5.375PercentDueAugust2014Member_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ConvertibleNotesPayable5.375PercentDueAugust2014Member_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ConvertibleNotesPayable5.375PercentDueAugust2014Member_ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ConvertibleNotesPayable5.375PercentDueAugust2014Member_SE">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:ConvertibleNotesPayable5.375PercentDueAugust2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_BrazilUncommittedLineOfCreditMember_DebtInstrumentInterbankDepositCertificateRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:BrazilUncommittedLineOfCreditMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentInterbankDepositCertificateRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_SeniorSecuredTermLoanBFacilityMember_DebtInstrumentVariableRateBaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrx:SeniorSecuredTermLoanBFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="vrx:DebtInstrumentVariableRateBaseAxis">vrx:DebtInstrumentVariableRateBaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M0911_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-09-10</xbrli:startDate>
      <xbrli:endDate>2012-09-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_OraPharmaMember_ScenarioAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:OraPharmaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ContingentConsiderationArrangementMember_LacricertMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vrx:ContingentConsiderationArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:LacricertMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ContingentConsiderationArrangementMember_ElidelXereseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vrx:ContingentConsiderationArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">vrx:ElidelXereseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_InovaPharmaceuticalsMember_ContingentConsiderationArrangementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:InovaPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vrx:ContingentConsiderationArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_DebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0911_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_USDermatologyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vrx:USDermatologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0924_QLTIncAndQLTOphthalmicsIncMember_SegmentGeographicalGroupsOfCountriesGroupOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vrx:QLTIncAndQLTOphthalmicsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:SegmentGeographicalGroupsOfCountriesGroupOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_RestrictedStockUnitsRSUMember_SellingGeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">vrx:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1029_AnacorPharmaceuticalsMember_MasterServicesAgreementMember_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vrx:AnacorPharmaceuticalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">vrx:MasterServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-28</xbrli:startDate>
      <xbrli:endDate>2012-10-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="EUR">
    <xbrli:measure>iso4217:EUR</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="AUD">
    <xbrli:measure>iso4217:AUD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="BRL">
    <xbrli:measure>iso4217:BRL</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="MXN">
    <xbrli:measure>iso4217:MXN</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Item">
    <xbrli:measure>vrx:item</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="EURPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:EUR</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="CADPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:CAD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="Tag1" decimals="-3" contextRef="I2011" unitRef="USD">6338000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:ReceivablesNetCurrent id="Tag2" decimals="-3" contextRef="I2011" unitRef="USD">569268000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:InventoryNet id="Tag3" decimals="-3" contextRef="I2011" unitRef="USD">355212000</us-gaap:InventoryNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag4" decimals="-3" contextRef="I2011" unitRef="USD">41884000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsHeldForSaleCurrent id="Tag5" decimals="-3" contextRef="I2011" unitRef="USD">72239000</us-gaap:AssetsHeldForSaleCurrent>
  <us-gaap:DeferredTaxAssetsLiabilitiesNetCurrent id="Tag6" decimals="-3" contextRef="I2011" unitRef="USD">148454000</us-gaap:DeferredTaxAssetsLiabilitiesNetCurrent>
  <us-gaap:AssetsCurrent id="Tag7" decimals="-3" contextRef="I2011" unitRef="USD">1357506000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag8" decimals="-3" contextRef="I2011" unitRef="USD">414242000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Goodwill id="Tag9" decimals="-3" contextRef="I2011" unitRef="USD">3598786000</us-gaap:Goodwill>
  <us-gaap:DeferredTaxAssetsNetNoncurrent id="Tag10" decimals="-3" contextRef="I2011" unitRef="USD">54681000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="Tag11" decimals="-3" contextRef="I2011" unitRef="USD">58700000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="Tag12" decimals="-3" contextRef="I2011" unitRef="USD">13141713000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="Tag13" decimals="-3" contextRef="I2011" unitRef="USD">157620000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Tag14" decimals="-3" contextRef="I2011" unitRef="USD">527583000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:BusinessAcquisitionContingentConsiderationAtFairValueCurrent id="Tag15" decimals="-3" contextRef="I2011" unitRef="USD">100263000</us-gaap:BusinessAcquisitionContingentConsiderationAtFairValueCurrent>
  <us-gaap:AccruedIncomeTaxesCurrent id="Tag16" decimals="-3" contextRef="I2011" unitRef="USD">10335000</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:DeferredRevenueCurrent id="Tag17" decimals="-3" contextRef="I2011" unitRef="USD">12783000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LongTermDebtCurrent id="Tag18" decimals="-3" contextRef="I2011" unitRef="USD">111250000</us-gaap:LongTermDebtCurrent>
  <us-gaap:DeferredTaxLiabilitiesCurrent id="Tag19" decimals="-3" contextRef="I2011" unitRef="USD">4438000</us-gaap:DeferredTaxLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag20" decimals="-3" contextRef="I2011" unitRef="USD">924272000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="Tag21" decimals="-3" contextRef="I2011" unitRef="USD">38153000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent id="Tag22" decimals="-3" contextRef="I2011" unitRef="USD">319821000</us-gaap:BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="Tag23" decimals="-3" contextRef="I2011" unitRef="USD">6539761000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent id="Tag24" decimals="-3" contextRef="I2011" unitRef="USD">91098000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent id="Tag25" decimals="-3" contextRef="I2011" unitRef="USD">1144914000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="Tag26" decimals="-3" contextRef="I2011" unitRef="USD">76678000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:Liabilities id="Tag27" decimals="-3" contextRef="I2011" unitRef="USD">9134697000</us-gaap:Liabilities>
  <us-gaap:CommonStockValue id="Tag28" decimals="-3" contextRef="I2011" unitRef="USD">5963621000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="Tag29" decimals="-3" contextRef="I2011" unitRef="USD">276117000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Tag30" decimals="-3" contextRef="I2011" unitRef="USD">-2030292000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="Tag31" decimals="-3" contextRef="I2011" unitRef="USD">-202430000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockholdersEquity id="Tag32" decimals="-3" contextRef="I2011" unitRef="USD">4007016000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag33" decimals="-3" contextRef="I2011" unitRef="USD">13141713000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag34" decimals="-3" contextRef="I2012Q3" unitRef="USD">14146208000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockSharesIssued id="Tag35" decimals="INF" contextRef="I2012Q3" unitRef="Shares">302899442</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="Tag36" decimals="INF" contextRef="I2011" unitRef="Shares">306371032</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Tag37" decimals="INF" contextRef="I2012Q3" unitRef="Shares">302899442</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="Tag38" decimals="INF" contextRef="I2011" unitRef="Shares">306371032</us-gaap:CommonStockSharesOutstanding>
  <dei:EntityRegistrantName id="Tag39" contextRef="D2012Q3YTD">Valeant Pharmaceuticals International, Inc.</dei:EntityRegistrantName>
  <us-gaap:Liabilities id="Tag40" decimals="-3" contextRef="I2012Q3" unitRef="USD">10361026000</us-gaap:Liabilities>
  <dei:EntityCentralIndexKey id="Tag41" contextRef="D2012Q3YTD">0000885590</dei:EntityCentralIndexKey>
  <dei:DocumentType id="Tag42" contextRef="D2012Q3YTD">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate id="Tag43" contextRef="D2012Q3YTD">2012-09-30</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag id="Tag44" contextRef="D2012Q3YTD">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="Tag45" contextRef="D2012Q3YTD">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCurrentReportingStatus id="Tag46" contextRef="D2012Q3YTD">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="Tag47" contextRef="D2012Q3YTD">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="Tag48" decimals="INF" contextRef="I2012Q3SO" unitRef="Shares">304823911</dei:EntityCommonStockSharesOutstanding>
  <dei:DocumentFiscalYearFocus id="Tag49" contextRef="D2012Q3YTD">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="Tag50" contextRef="D2012Q3YTD">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:SalesRevenueGoodsNet id="Tag51" decimals="-3" contextRef="D2012Q3" unitRef="USD">856892000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet id="Tag52" decimals="-3" contextRef="D2011Q3" unitRef="USD">570423000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet id="Tag53" decimals="-3" contextRef="D2011Q3YTD" unitRef="USD">1600879000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:RoyaltyRevenue id="Tag54" decimals="-3" contextRef="D2012Q3" unitRef="USD">12248000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue id="Tag55" decimals="-3" contextRef="D2011Q3" unitRef="USD">22471000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue id="Tag56" decimals="-3" contextRef="D2011Q3YTD" unitRef="USD">146873000</us-gaap:RoyaltyRevenue>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned id="Tag57" decimals="-3" contextRef="D2012Q3" unitRef="USD">15000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned id="Tag58" decimals="-3" contextRef="D2011Q3" unitRef="USD">7690000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned id="Tag59" decimals="-3" contextRef="D2011Q3YTD" unitRef="USD">27245000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:Revenues id="Tag60" decimals="-3" contextRef="D2012Q3" unitRef="USD">884140000</us-gaap:Revenues>
  <us-gaap:Revenues id="Tag61" decimals="-3" contextRef="D2011Q3" unitRef="USD">600584000</us-gaap:Revenues>
  <us-gaap:Revenues id="Tag62" decimals="-3" contextRef="D2011Q3YTD" unitRef="USD">1774997000</us-gaap:Revenues>
  <us-gaap:CostOfGoodsSold id="Tag63" decimals="-3" contextRef="D2012Q3" unitRef="USD">219670000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold id="Tag64" decimals="-3" contextRef="D2011Q3" unitRef="USD">162568000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold id="Tag65" decimals="-3" contextRef="D2011Q3YTD" unitRef="USD">501767000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfServicesLicensesAndServices id="Tag66" decimals="-3" contextRef="D2012Q3" unitRef="USD">10582000</us-gaap:CostOfServicesLicensesAndServices>
  <us-gaap:CostOfServicesLicensesAndServices id="Tag67" decimals="-3" contextRef="D2011Q3" unitRef="USD">3078000</us-gaap:CostOfServicesLicensesAndServices>
  <us-gaap:CostOfServicesLicensesAndServices id="Tag68" decimals="-3" contextRef="D2011Q3YTD" unitRef="USD">40418000</us-gaap:CostOfServicesLicensesAndServices>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag69" decimals="-3" contextRef="D2012Q3" unitRef="USD">188660000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag70" decimals="-3" contextRef="D2011Q3" unitRef="USD">134801000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag71" decimals="-3" contextRef="D2011Q3YTD" unitRef="USD">423964000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost id="Tag72" decimals="-3" contextRef="D2012Q3" unitRef="USD">19170000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost id="Tag73" decimals="-3" contextRef="D2011Q3" unitRef="USD">17476000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost id="Tag74" decimals="-3" contextRef="D2011Q3YTD" unitRef="USD">48910000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <vrx:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold id="Tag75" decimals="-3" contextRef="D2012Q3" unitRef="USD">218187000</vrx:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
  <vrx:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold id="Tag76" decimals="-3" contextRef="D2011Q3" unitRef="USD">138027000</vrx:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
  <us-gaap:EarningsPerShareBasic id="Tag77" decimals="2" contextRef="D2011Q3YTD" unitRef="USDPerShare">0.34</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted id="Tag78" decimals="2" contextRef="D2011Q3YTD" unitRef="USDPerShare">0.32</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Tag79" decimals="-3" contextRef="D2011Q3YTD" unitRef="Shares">303285000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Tag80" decimals="-3" contextRef="D2011Q3YTD" unitRef="Shares">329010000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <vrx:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold id="Tag81" decimals="-3" contextRef="D2011Q3YTD" unitRef="USD">365016000</vrx:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="Tag82" decimals="-3" contextRef="D2012Q3" unitRef="USD">106731000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="Tag83" decimals="-3" contextRef="D2011Q3" unitRef="USD">-471075000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:RestructuringCharges id="Tag84" decimals="-3" contextRef="D2012Q3" unitRef="USD">42872000</us-gaap:RestructuringCharges>
  <vrx:PaymentsOfContingentConsideration id="Tag85" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">79844000</vrx:PaymentsOfContingentConsideration>
  <us-gaap:RepaymentsOfShortTermDebt id="Tag86" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">26402000</us-gaap:RepaymentsOfShortTermDebt>
  <us-gaap:ProceedsFromShortTermDebt id="Tag87" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">28530000</us-gaap:ProceedsFromShortTermDebt>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag88" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">-991916000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="Tag89" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">8245000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag90" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">588659000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <vrx:PaymentOfAccretedInterestOnContingentConsideration id="Tag91" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">1450000</vrx:PaymentOfAccretedInterestOnContingentConsideration>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Tag92" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">21909000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag93" decimals="-3" contextRef="I2012Q3" unitRef="USD">257730000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag94" decimals="-3" contextRef="I2011Q2" unitRef="USD">238945000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag95" decimals="-3" contextRef="I2012Q2" unitRef="USD">395266000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestructuringReserve id="Tag96" decimals="-3" contextRef="I2012Q3_SeveranceAndRelatedBenefitsMember" unitRef="USD">269000</us-gaap:RestructuringReserve>
  <us-gaap:RestructuringReserve id="Tag97" decimals="-3" contextRef="I2012Q3_ContractTerminationFacilityClosureAndOtherCostsMember" unitRef="USD">433000</us-gaap:RestructuringReserve>
  <us-gaap:RestructuringCharges id="Tag98" decimals="-3" contextRef="D2012Q3_ContractTerminationFacilityClosureAndOtherCostsMember" unitRef="USD">252000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringReserveSettledWithCash id="Tag99" decimals="-3" contextRef="D2012Q3_SeveranceAndRelatedBenefitsMember" unitRef="USD">80000</us-gaap:RestructuringReserveSettledWithCash>
  <us-gaap:RestructuringReserveSettledWithCash id="Tag100" decimals="-3" contextRef="D2012Q3_ContractTerminationFacilityClosureAndOtherCostsMember" unitRef="USD">81000</us-gaap:RestructuringReserveSettledWithCash>
  <us-gaap:RestructuringReserveSettledWithCash id="Tag101" decimals="-3" contextRef="D2012Q3" unitRef="USD">161000</us-gaap:RestructuringReserveSettledWithCash>
  <us-gaap:RestructuringReserveSettledWithoutCash id="Tag102" decimals="-3" contextRef="D2012Q3_SeveranceAndRelatedBenefitsMember" unitRef="USD">134000</us-gaap:RestructuringReserveSettledWithoutCash>
  <us-gaap:RestructuringReserveSettledWithoutCash id="Tag103" decimals="-3" contextRef="D2012Q3_ContractTerminationFacilityClosureAndOtherCostsMember" unitRef="USD">-15000</us-gaap:RestructuringReserveSettledWithoutCash>
  <us-gaap:RestructuringReserveSettledWithoutCash id="Tag104" decimals="-3" contextRef="D2012Q3" unitRef="USD">119000</us-gaap:RestructuringReserveSettledWithoutCash>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag105" decimals="-3" contextRef="I2012Q1" unitRef="USD">330479000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag106" decimals="-3" contextRef="I2011Q1" unitRef="USD">401752000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag107" decimals="-3" contextRef="I2011Q3" unitRef="USD">254559000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag108" decimals="-3" contextRef="I2010" unitRef="USD">394269000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag109" decimals="-3" contextRef="I2011" unitRef="USD">164111000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="Tag110" decimals="-3" contextRef="D2011Q3YTD" unitRef="USD">-287635000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <vrx:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnEquitySecuritiesArisingDuringPeriodNetOfTax id="Tag111" decimals="-3" contextRef="D2011Q3" unitRef="USD">-21000</vrx:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnEquitySecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:NatureOfOperations id="Tag112" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; DESCRIPTION OF BUSINESS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On September&amp;#160;28, 2010 (the &amp;#8220;Merger Date&amp;#8221;), Biovail Corporation (&amp;#8220;Biovail&amp;#8221;) completed the acquisition of Valeant Pharmaceuticals International (&amp;#8220;Valeant&amp;#8221;) through a wholly-owned subsidiary pursuant to an Agreement and Plan of Merger, dated as of June&amp;#160;20, 2010, with Valeant surviving as a wholly-owned subsidiary of Biovail (the &amp;#8220;Merger&amp;#8221;). In connection with the Merger, Biovail was renamed &amp;#8220;Valeant Pharmaceuticals International,&amp;#160;Inc.&amp;#8221; (the &amp;#8220;Company&amp;#8221;). The Company is a multinational, specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:NatureOfOperations>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="Tag113" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2.&lt;/font&gt;&lt;/b&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Basis of Presentation&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The accompanying unaudited consolidated financial statements (the&amp;#160;&amp;#8220;unaudited consolidated financial statements&amp;#8221;) have been prepared by the Company in United&amp;#160;States (&amp;#8220;U.S.&amp;#8221;) dollars and in accordance with U.S.&amp;#160;generally accepted accounting principles (&amp;#8220;U.S.&amp;#160;GAAP&amp;#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&amp;#160;GAAP for annual financial statements. Accordingly, these condensed notes to the unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto prepared in accordance with U.S.&amp;#160;GAAP that are contained in the Company&amp;#8217;s Annual Report on Form&amp;#160;10-K for the year ended December&amp;#160;31, 2011 (the&amp;#160;&amp;#8220;2011 Form&amp;#160;10-K&amp;#8221;). The unaudited consolidated financial statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&amp;#8217;s audited consolidated financial statements for the year ended December&amp;#160;31, 2011. There have been no changes to the Company&amp;#8217;s significant accounting policies since December&amp;#160;31, 2011, except as described below under &amp;#8220;Adoption of New&amp;#160;Accounting Standards&amp;#8221;. The unaudited consolidated financial statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&amp;#8217;s financial position and results of operations for the interim periods presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Reclassifications and Revisions&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Certain reclassifications have been made to prior year amounts to conform with the current year presentation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company has revised the 2011 consolidated statement of cash flows for the presentation of the proceeds from the out-license of an intangible asset to conform to the current year presentation. The Company decreased Net cash used in investing activities with an offsetting decrease in Net cash provided by operating activities by $36.0 million for the nine-month period ended September&amp;#160;30, 2011. This revision did not have a material impact to the Company&amp;#8217;s previously reported consolidated statement of cash flows. This change had no effect on the Company&amp;#8217;s previously reported consolidated balance sheets, consolidated statements of income (loss) and consolidated statements of comprehensive income (loss).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Use of Estimates&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In preparing the unaudited consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the unaudited consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full&amp;#160;year.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&amp;#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&amp;#8217;s results of operations and financial position could be materially impacted.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Adoption of New&amp;#160;Accounting Standards&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Effective January&amp;#160;1, 2012, the Company has adopted on a prospective basis the provisions of the following new accounting standards:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Guidance that results in a consistent definition of fair value and common requirements for measurement of and disclosure about fair value between U.S.&amp;#160;GAAP and International Financial Reporting Standards (&amp;#8220;IFRS&amp;#8221;). The amendments change some fair value measurement principles and disclosure requirements under U.S.&amp;#160;GAAP. The adoption of this guidance did not have a significant impact on the Company&amp;#8217;s financial position or results of&amp;#160;operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Guidance requiring entities to present net income and other comprehensive income in either a single continuous statement or in two separate, but consecutive, statements of net income and other comprehensive income. This guidance does not change the components of other comprehensive income or the calculation of earnings per share. The effective date for amendments to the presentation of reclassifications out of accumulated other comprehensive income has been deferred. As this guidance relates to presentation only, the adoption of this guidance did not impact the Company&amp;#8217;s financial position or results of&amp;#160;operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Guidance intended to simplify goodwill impairment testing, by allowing an entity to first assess qualitative factors to determine whether it is &amp;#8220;more likely than not&amp;#8221; that the fair value of a reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform a two-step goodwill impairment test. The more-likely-than-not threshold is defined as having a likelihood of more than 50%. The adoption of this guidance did not have a significant impact on the Company&amp;#8217;s financial position or results of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In July&amp;#160;2012, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued guidance intended to simplify indefinite-lived intangible impairment testing, by allowing an entity to first assess qualitative factors to determine whether it is &amp;#8220;more likely than not&amp;#8221; that the fair value of an asset is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative impairment test. The more-likely-than-not threshold is defined as having a likelihood of more than 50%. This guidance is effective for annual and interim tests performed for fiscal years beginning after September&amp;#160;15, 2012. The adoption of this guidance is not expected to have a significant impact on the Company&amp;#8217;s financial position or results of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:BusinessCombinationDisclosureTextBlock id="Tag114" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',times,serif"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3.&lt;/font&gt;&lt;/b&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;b&gt;BUSINESS COMBINATIONS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company has focused its business on core geographies and therapeutic classes through selective acquisitions, dispositions and strategic partnerships with other pharmaceutical companies.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;(a)&amp;#160;Business combinations in 2012 include the following:&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;OraPharma&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Description of the Transaction&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On June 18, 2012, the Company acquired OraPharma Topco Holdings, Inc. (&amp;#8220;OraPharma&amp;#8221;), a specialty oral health company located in the U.S. that develops and commercializes products that improve and maintain oral health. The Company made an up-front payment of $289.3 million, and the Company may pay a series of contingent consideration payments of up to $114.0 million based on certain milestones, including certain revenue targets. The fair value of the contingent consideration was determined to be $99.2 million as of the acquisition date, for a total fair value of consideration transferred of $388.5 million. As of &lt;font style="COLOR: black" color="black"&gt;September&amp;#160;30, 2012&lt;/font&gt;, the assumptions used for determining fair value of the contingent consideration have not changed significantly from those used at the acquisition date. The Company also repaid at the closing $37.9 million of assumed debt.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;OraPharma&amp;#8217;s lead product is Arestin&lt;font style="POSITION: relative; TOP: -4pt"&gt;&amp;#174;&lt;/font&gt;, a locally administered antibiotic for the treatment of periodontitis that utilizes an advanced controlled-release delivery system and is indicated for use in conjunction with scaling and root planing for the treatment of adult periodontitis.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Assets Acquired and Liabilities Assumed&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The transaction has been accounted for as a business combination under the acquisition method of accounting. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date. The following recognized amounts are provisional and subject to change:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;amounts for intangible assets, property, plant and equipment and inventories, pending finalization of the valuation;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;amounts for income tax assets and liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction;&amp;#160;and&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;amount of goodwill pending the completion of the valuation of the assets acquired and liabilities assumed.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company will finalize these amounts as it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in retrospective adjustments to the provisional amounts recognized at the acquisition date. These changes could be significant. The Company will finalize these amounts no later than one year from the acquisition date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Recognized&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Acquisition&amp;#160;Dates(a)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Measurement&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Period&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Adjustments(b)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Recognized&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(as&amp;#160;adjusted)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;14,119&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;14,119&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Accounts receivable(c)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;10,348&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;10,348&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Inventories&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3,222&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(685&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,537&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other current assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;4,063&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;22&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;4,085&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Property and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8,181&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8,181&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Identifiable intangible assets, excluding acquired IPR&amp;amp;D(d)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;466,408&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(64,095&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;402,313&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Acquired IPR&amp;amp;D(e)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;15,464&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;13,151&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;28,615&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other non-current assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,862&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,862&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Current liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(9,675&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(395&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(10,070&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt, including current portion(f)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(37,868&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(37,868&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Deferred income taxes, net&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(173,907&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;18,386&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(155,521&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other non-current liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(158&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(158&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total identifiable net assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;302,059&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(33,616&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;268,443&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Goodwill(g)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;86,802&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;33,255&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;120,057&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total fair value of consideration transferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;388,861&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(361&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 2.25pt; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;388,500&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(a)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;As previously reported in the Company&amp;#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(b)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The measurement period adjustments primarily reflect: (i) changes in the estimated fair value of the Arestin&lt;font style="POSITION: relative; TOP: -4pt"&gt;&amp;#174; &lt;/font&gt;product brand; (ii) the reclassification of intangible assets from product brands to acquired in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;); (iii) a decrease in the total fair value of consideration transferred due to a working capital adjustment; and (iv) the tax impact of pre-tax measurement period adjustments. The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company&amp;#8217;s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(c)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Both the fair value and gross contractual amount of trade accounts receivable acquired were &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black" color="black" size="2"&gt;$10.3 million&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;, as the Company expects that the amount to be uncollectible is negligible.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(d)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 52.65pt; WIDTH: 90.28%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="90%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 38.98%; PADDING-TOP: 0in" valign="bottom" width="38%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Weighted-&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;Average&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;
&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Useful&lt;br /&gt;
Lives&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(Years)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Recognized&amp;#160;as&lt;br /&gt;
of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Acquisition&lt;br /&gt;
Date&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.6%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Measurement&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Period&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Adjustments&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.6%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Recognized&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(as&lt;br /&gt;
adjusted)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 38.98%; PADDING-TOP: 0in" valign="bottom" width="38%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Product brand&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;12&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.06%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;446,958&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.6%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.06%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(62,450)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.6%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.1%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;384,508&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 38.98%; PADDING-TOP: 0in" valign="bottom" width="38%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Corporate brand&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.4%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;15&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;19,450&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.6%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(1,645&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.6%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17,805&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 38.98%; PADDING-TOP: 0in" valign="bottom" width="38%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total identifiable intangible assets acquired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.4%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;12&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.06%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;466,408&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.6%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.06%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(64,095)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.6%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.1%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;402,313&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(e)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The IPR&amp;amp;D assets primarily relate to the development of Arestin ER, which is indicated for oral hygiene use and Arestin Peri-Implantitis, which is indicated for anti-inflammatory and anti-bacterial use.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(f)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Effective June 18, 2012, the Company terminated the credit facility agreement, repaid the assumed debt outstanding and cancelled the undrawn credit facilities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(g)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the provisional values assigned to the assets acquired and liabilities assumed. None of the goodwill is expected to be deductible for tax purposes. The goodwill recorded represents the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;cost savings, operating synergies and other benefits expected to result from combining the operations of OraPharma with those of the Company;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;the value of the continuing operations of OraPharma&amp;#8217;s existing business (that is, the higher rate of return on the assembled net assets versus if the Company had acquired all of the net assets separately); and&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;intangible assets that do not qualify for separate recognition (for&amp;#160;instance, OraPharma&amp;#8217;s assembled workforce).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The provisional amount of goodwill has been allocated to the Company&amp;#8217;s U.S. Dermatology segment as indicated in note 10.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Acquisition-Related Costs&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company has incurred to date $3.7 million of transaction costs directly related to the OraPharma acquisition, which includes expenditures for advisory, legal, valuation, accounting and other similar services. These costs have been expensed as acquisition-related costs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Revenue and Net Loss of OraPharma&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The revenues of OraPharma for the period from the acquisition date to &lt;font style="COLOR: black" color="black"&gt;September&amp;#160;30, 2012&lt;/font&gt; were $28.3 million, and the net loss was $3.5 million. The net loss includes the effects of the acquisition accounting adjustments and acquisition-related costs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other Business Combinations&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Description of the Transactions&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In the nine-month period ended &lt;font style="COLOR: black" color="black"&gt;September&amp;#160;30, 2012&lt;/font&gt;, the Company completed other business combinations, which included the following businesses, as well as other smaller acquisitions, for an aggregate purchase price of &lt;font style="COLOR: black" color="black"&gt;$744.4 million&lt;/font&gt;. The aggregate purchase price included contingent consideration obligations with an aggregate acquisition date fair value of $44.2 million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On September 28, 2012, the Company acquired certain assets from Johnson &amp;amp; Johnson Consumer Companies, Inc. (&amp;#8220;J&amp;amp;J North America&amp;#8221;) for a purchase price of $109.6 million, relating to the U.S. and Canadian rights to the over-the-counter (&amp;#8220;OTC&amp;#8221;) consumer brands Ambi&lt;font style="POSITION: relative; TOP: -4pt"&gt;&amp;#174;&lt;/font&gt;, Caladryl&lt;font style="POSITION: relative; TOP: -4pt"&gt;&amp;#174;&lt;/font&gt;, Corn Huskers&lt;font style="POSITION: relative; TOP: -4pt"&gt;&amp;#174;&lt;/font&gt;, Cortaid&lt;font style="POSITION: relative; TOP: -4pt"&gt;&amp;#174;&lt;/font&gt;, Purpose&lt;font style="POSITION: relative; TOP: -4pt"&gt;&amp;#174;&lt;/font&gt;&amp;#160;and Shower to Shower&lt;font style="POSITION: relative; TOP: -4pt"&gt;&amp;#174;&lt;/font&gt;. &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On September 24, 2012, the Company acquired certain assets from QLT Inc. and QLT Ophthalmics, Inc. (collectively, &amp;#8220;QLT&amp;#8221;) relating to Visudyne&lt;font style="POSITION: relative; TOP: -4pt"&gt;&amp;#174;&lt;/font&gt;, which is used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration. The consideration paid included up-front payments of $62.5 million for the assets related to the rights to the product in the U.S. and $50.0 million for the assets related to the rights to the product outside the U.S. The Company may pay a series of contingent payments of up to $20.0 million relating to non-U.S. royalties and development milestones for QLT&amp;#8217;s laser program in the U.S. In addition, the Company will pay royalties on sales of potential new indications for Visudyne&lt;font style="POSITION: relative; TOP: -4pt"&gt;&amp;#174; &lt;/font&gt;in the U.S. The fair value of the contingent consideration was determined to be $7.9 million as of the acquisition date. As of &lt;font style="COLOR: black" color="black"&gt;September&amp;#160;30, 2012&lt;/font&gt;, the assumptions used for determining fair value of the contingent consideration have not changed significantly from those used at the acquisition date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On May 23, 2012, the Company acquired certain assets from University Medical Pharmaceuticals Corp. (&amp;#8220;University Medical&amp;#8221;), a specialty pharmaceutical company located in the U.S. focused on skincare products, including the rights to University Medical&amp;#8217;s main brand AcneFree&amp;#8482;, a retail OTC acne treatment. The consideration includes up-front payments of $65.0 million, and the Company may pay a series of contingent consideration payments of up to $40.0 million if certain net sales milestones are achieved. The fair value of the contingent consideration was determined to be $1.5 million as of the acquisition date. As of &lt;font style="COLOR: black" color="black"&gt;September&amp;#160;30, 2012&lt;/font&gt;, the assumptions used for determining fair value of the contingent consideration have not changed significantly from those used at the acquisition date. &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On May 2, 2012, the Company acquired certain assets from Atlantis Pharma (&amp;#8220;Atlantis&amp;#8221;), a branded generics pharmaceutical company located in Mexico, for up-front payments of $65.5 million (MXN$847.3 million), and the Company placed an additional $8.9 million (MXN$114.7 million) into an escrow account. The amounts in escrow will be paid to the sellers only if certain regulatory milestones are achieved and therefore such amounts were treated as contingent consideration. The fair value of the contingent consideration was determined to be $7.6 million as of the acquisition date. As of &lt;font style="COLOR: black" color="black"&gt;September&amp;#160;30, 2012&lt;/font&gt;, the assumptions used for determining fair value of the contingent consideration have not changed significantly from those used at the acquisition date. Since the acquisition date, certain amounts have been released from escrow to the sellers, reducing the escrow balance to &lt;font style="COLOR: black" color="black"&gt;$8.2 million&lt;/font&gt; as of September 30, 2012. The escrow balance is classified as Restricted cash in the Company&amp;#8217;s consolidated balance sheets. Atlantis has a broad product portfolio, including products in gastro, analgesics and anti-inflammatory therapeutic categories.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On March 13, 2012, the Company acquired certain assets from Gerot Lannach, a branded generics pharmaceutical company based in Austria. The Company made an up-front payment of $164.0 million (&amp;#8364;125.0 million), and the Company may pay a series of contingent consideration payments of up to $19.7 million (&amp;#8364;15.0 million) if certain net sales milestones are achieved. The fair value of the contingent consideration was determined to be $16.8 million as of the acquisition date. As of &lt;font style="COLOR: black" color="black"&gt;September&amp;#160;30, 2012&lt;/font&gt;, the assumptions used for determining fair value of the contingent consideration have not changed significantly from those used at the acquisition date. As part of the transaction, the Company also entered into a ten-year exclusive supply agreement with Gerot Lannach for the acquired products. Approximately 90% of sales relating to the acquired assets are in Russia, with sales also made in certain Commonwealth of Independent States (CIS) countries including Kazakhstan and Uzbekistan. Gerot Lannach&amp;#8217;s largest product is acetylsalicylic acid, a low dose aspirin.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On February 1, 2012, the Company acquired Probiotica Laboratorios Ltda. (&amp;#8220;Probiotica&amp;#8221;), which markets OTC sports nutrition products and other food supplements in Brazil, for a purchase price of $90.5 million (R$158.0 million).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;During the nine months ended September 30, 2012, the Company completed other smaller acquisitions which are not material individually or in the aggregate. These acquisitions are included in the aggregated amounts presented below.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Assets Acquired and Liabilities Assumed&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;These transactions have been accounted for as business combinations under the acquisition method of accounting. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the other business combinations, in the aggregate, as of the acquisition dates. The following recognized amounts with respect to the J&amp;amp;J North America, QLT, University Medical and Probiotica, and certain other smaller&amp;#160;acquisitions are provisional and subject to change:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;amounts for intangible assets, property, plant and equipment and inventories, pending finalization of the valuation;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;amounts for non-current liabilities, and corresponding indemnification assets, pending finalization of the assessment of contingent liabilities;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;amounts for income tax assets and liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction;&amp;#160;and&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;amount of goodwill pending the completion of the valuation of the assets acquired and liabilities assumed.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company will finalize these amounts as it obtains the information necessary to complete the measurement processes. Any changes resulting from facts and circumstances that existed as of the acquisition dates may result in retrospective adjustments to the provisional amounts recognized at the acquisition dates. These changes could be significant. The Company will finalize these amounts no later than one year from the respective acquisition&amp;#160;dates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Recognized&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Acquisition&amp;#160;Dates&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Measurement&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Period&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Adjustments(a)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Recognized&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(as&amp;#160;adjusted)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6,459&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(258&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6,201&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Accounts receivable(b)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;28,281&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(17&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;28,264&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Assets held for sale(c)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;15,566&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;15,566&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Inventories&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;59,884&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(121&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;59,763&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other current assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,523&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,523&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7,209&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7,209&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Identifiable intangible assets, excluding acquired IPR&amp;amp;D(d)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;601,412&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,852&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;604,264&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Acquired IPR&amp;amp;D&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,234&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,234&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Indemnification assets(e)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;27,901&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;27,901&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Current liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(30,815&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(350&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(31,165&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Liability for uncertain tax position&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(6,682&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6,682&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other non-current liabilities(e)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(27,901&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(27,901&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Deferred income taxes, net&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(9,198&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;373&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(8,825&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total identifiable net assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;675,873&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;9,161&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;685,034&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Goodwill(f)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;68,612&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(9,239&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;59,373&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 55.5%; PADDING-TOP: 0in" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total fair value of consideration transferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;744,485&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(78&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;744,407&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(a)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The measurement period adjustments relate to the Probiotica acquisition and primarily reflect: (i) the elimination of the liability for uncertain tax positions; (ii) the changes in the estimated fair value of the corporate brand intangible asset; and (iii) a decrease in the total fair value of consideration transferred due to a working capital adjustment. The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company&amp;#8217;s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(b)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The fair value of trade accounts receivable acquired was &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; COLOR: black" color="black" size="2"&gt;$28.3 million&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;, with the gross contractual amount being $29.6 million, of which the Company expects that $1.3 million will be uncollectible.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(c)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Assets held for sale relate to a product brand acquired in the Atlantis acquisition. Subsequent to that acquisition, the plan of sale changed, and the Company no longer intends to sell the asset. Consequently, the product brand is not classified as an asset held for sale as of September 30, 2012. &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(d)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 50.85pt; WIDTH: 90.62%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="90%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 39.24%; PADDING-TOP: 0in" valign="bottom" width="39%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Weighted-&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Useful&amp;#160;Lives&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(Years)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Recognized&amp;#160;as&lt;br /&gt;
of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Acquisition&lt;br /&gt;
Date&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Measurement&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Period&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Adjustments&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Recognized&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(as&lt;br /&gt;
adjusted)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 39.24%; PADDING-TOP: 0in" valign="bottom" width="39%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Product brands&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.36%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.02%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;393,427&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.02%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.02%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;393,427&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 39.24%; PADDING-TOP: 0in" valign="bottom" width="39%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Corporate brands&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;12&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;31,503&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3,725&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;35,228&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 39.24%; PADDING-TOP: 0in" valign="bottom" width="39%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Product rights&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;10&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;109,274&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(873&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;108,401&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 39.24%; PADDING-TOP: 0in" valign="bottom" width="39%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Royalty agreement&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;36,277&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;36,277&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 39.24%; PADDING-TOP: 0in" valign="bottom" width="39%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Partner relationships&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;30,931&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.36%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;30,931&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 39.24%; PADDING-TOP: 0in" valign="bottom" width="39%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total identifiable intangible assets acquired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.36%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;10&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;601,412&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,852&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.58%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;604,264&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(e)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other non-current liabilities, and the corresponding indemnification assets, primarily relate to certain asserted and unasserted claims against Probiotica, which include potential tax-related obligations that existed at the acquisition date. The Company is indemnified by the sellers in accordance with indemnification provisions under its contractual arrangements. Indemnification assets and contingent liabilities were recorded at the same amount and classified in the same manner, as components of the purchase price, representing our best estimates of these amounts at the acquisition date, in accordance with guidance for loss contingencies and uncertain tax positions. Under the Company&amp;#8217;s contractual arrangement with Probiotica, there is no limitation on the amount or value of indemnity claims that can be made by the Company; however there is a time restriction of either two or five years, depending on the nature of the claim. Approximately $12.9 million (R$22.5 million) of the purchase price for the Probiotica transaction from the date of acquisition has been placed in escrow in accordance with the indemnification provisions. The escrow account will be maintained for two years, with 50% being released to the sellers after the first year, and the remaining balance released after the second year. The Company expects the total amount of such indemnification assets to be collectible from the sellers. The Company is continuing to gather and assess information with respect to the non-current liabilities and indemnification assets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(f)&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The goodwill relates primarily to the Probiotica acquisition. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the provisional values assigned to the assets acquired and liabilities assumed. The Company expects that the goodwill will be deductible for tax purposes. The goodwill recorded from the J&amp;amp;J North America, QLT, University Medical, Atlantis and Gerot Lannach acquisitions represents primarily the cost savings, operating synergies and other benefits expected to result from combining the operations with those of the Company. Probiotica&amp;#8217;s goodwill recorded represents the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;the Company&amp;#8217;s expectation to develop and market new product brands and product lines in the&amp;#160;future;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;the value associated with the Company&amp;#8217;s ability to develop relationships with new customers;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;the value of the continuing operations of Probiotica&amp;#8217;s existing business (that is, the higher rate of return on the assembled net assets versus if the Company had acquired all of the net assets separately); and&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;intangible assets that do not qualify for separate recognition (for instance, Probiotica&amp;#8217;s assembled workforce).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The provisional amount of the goodwill from the J&amp;amp;J North America, QLT and University Medical acquisitions has been allocated to the Company&amp;#8217;s U.S. Dermatology segment. The provisional amount of the goodwill from the Probiotica acquisition, and the amounts of goodwill from the Atlantis and Gerot Lannach acquisitions, have been allocated to the Company&amp;#8217;s Emerging Markets segment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Acquisition-Related Costs&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company has incurred to date $9.0&lt;b&gt; &lt;/b&gt;million, in the aggregate, of transaction costs directly related to the other business combinations, which includes expenditures for advisory, legal, valuation, accounting and other similar services. These costs have been expensed as acquisition-related costs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Revenue and Net Loss of Other Business Combinations&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The revenues of the other business combinations for the period from the respective acquisition dates to &lt;font style="COLOR: black" color="black"&gt;September&amp;#160;30, 2012&lt;/font&gt; were $106.6 million, in the aggregate, and the net loss was $10.5 million, in the aggregate. The net loss includes the effects of the acquisition accounting adjustments and acquisition-related costs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;(b) Business combinations in 2011 include the following:&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;iNova&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Description of the Transaction&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On December&amp;#160;21, 2011, the Company acquired iNova from Archer Capital,&amp;#160;Ironbridge Capital and other minority management shareholders. The Company made up-front payments of $656.7 million (AUD$657.9 million) and the Company may pay a series of potential milestones of up to $59.9 million (AUD$60 million) based on the success of pipeline activities, product registrations and overall revenue. The fair value of the contingent consideration was determined to be $44.5 million as of the acquisition date, for a total fair value of consideration transferred of $701.2 million. As of September&amp;#160;30, 2012, the assumptions used for determining the fair value of the acquisition-related contingent consideration have not changed significantly from those used at the acquisition date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;iNova sells and distributes a range of prescription and OTC products in Australia, New Zealand, Asia and South Africa, including leading therapeutic weight management brands such as Duromine&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;/Metermine&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;, as well as leading OTC brands in the cold and cough area, such as Difflam&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;, Duro-Tuss&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;and Rikodeine&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Assets Acquired and Liabilities Assumed&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The transaction has been accounted for as a business combination under the acquisition method of accounting. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Acquisition&amp;#160;Date(a)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Measurement&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Period&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Adjustments(b)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(as&amp;#160;adjusted)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.72%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8,792&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.58%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.58%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8,792&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Accounts receivable(c)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;30,525&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;30,525&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Inventories&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;43,387&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(1,400&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;41,987&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant and equipment(d)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;15,257&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(749&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;14,508&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Identifiable intangible assets(e)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;423,950&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(2,188&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;421,762&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Deferred income taxes, net&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;15,893&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;15,893&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Current liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(32,500&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(1,713&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(34,213&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total identifiable net assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.02%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;489,411&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;9,843&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;499,254&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Goodwill(f)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;211,770&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(9,843&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;201,927&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total fair value of consideration transferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.72%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;701,181&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.58%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.58%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;701,181&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(a)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;As previously reported in the 2011 Form&amp;#160;10-K.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(b)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The measurement period adjustments primarily reflect: (i)&amp;#160;resolution of certain tax aspects of the transaction and the tax impact of pre-tax measurement period adjustments; (ii)&amp;#160;changes in the estimated fair value of an intangible asset and the related inventory; (iii)&amp;#160;additional information obtained with respect to the fair value of an acquired manufacturing facility; and (iv)&amp;#160;additional information obtained with respect to the valuation of compensation-related liabilities. The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company&amp;#8217;s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(c)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The fair value of trade accounts receivable acquired was $30.5 million, with the gross contractual amount being $31.5 million, of which the Company expects that $1.0 million will be uncollectible.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(d)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Property, plant and equipment includes a manufacturing facility, included in the Canada and Australia segment, which was subsequently sold during the third quarter of 2012 for $10.2 million, which equaled its carrying amount.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(e)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The following table summarizes the amounts and useful lives assigned to identifiable intangible assets:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.75in; WIDTH: 90%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="90%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 34.58%; PADDING-TOP: 0in" valign="bottom" width="34%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Weighted-&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Useful&amp;#160;Lives&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(Years)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Acquisition&amp;#160;Date&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Measurement&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Period&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Adjustments&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(as&amp;#160;adjusted)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 0.98%; PADDING-TOP: 0in" valign="bottom" width="0%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 34.58%; PADDING-TOP: 0in" valign="bottom" width="34%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Product brands&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.98%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;418,252&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.98%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(2,188&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.98%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;416,064&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 0.98%; PADDING-TOP: 0in" valign="bottom" width="0%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 34.58%; PADDING-TOP: 0in" valign="bottom" width="34%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Corporate brands&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.34%; PADDING-TOP: 0in" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;5,698&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;5,698&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 0.98%; PADDING-TOP: 0in" valign="bottom" width="0%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 34.58%; PADDING-TOP: 0in" valign="bottom" width="34%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total identifiable intangible assets acquired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.34%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.98%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;423,950&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.98%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(2,188&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 2.25pt; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.98%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;421,762&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 0.98%; PADDING-TOP: 0in" valign="bottom" width="0%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(f)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. None of the goodwill is expected to be deductible for tax purposes. The goodwill recorded represents the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;cost savings, operating synergies and other benefits expected to result from combining the operations of iNova with those of the Company;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;the value of the continuing operations of iNova&amp;#8217;s existing business (that is, the higher rate of return on the assembled net assets versus if the Company had acquired all of the net assets separately); and&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;intangible assets that do not qualify for separate recognition (for instance, iNova&amp;#8217;s assembled workforce).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The goodwill has been allocated to the Company&amp;#8217;s Canada and Australia segment ($119.5 million) and the Company&amp;#8217;s Emerging Markets segment ($82.4 million).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Dermik&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Description of the Transaction&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On December&amp;#160;16, 2011, the Company acquired Dermik, a dermatological unit of Sanofi in the U.S. and Canada, as well as the worldwide rights to Sculptra&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;and Sculptra&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;Aesthetic, for a total cash purchase price of approximately $421.6 million. The acquisition includes Dermik&amp;#8217;s inventories and manufacturing facility located in Laval, Quebec. In connection with the acquisition of Dermik, the Company was required by the Federal Trade Commission (&amp;#8220;FTC&amp;#8221;) to divest 1% clindamycin and 5% benzoyl peroxide gel, a generic version of BenzaClin&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;, and 5% fluorouracil cream, an authorized generic of Efudex&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;. For further details, see note 4 titled &amp;#8220;ACQUISITIONS AND DISPOSITIONS&amp;#8221;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Dermik is a leading global medical dermatology business focused on the manufacturing, marketing and sale of therapeutic and aesthetic dermatology products.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Assets Acquired and Liabilities Assumed&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The transaction has been accounted for as a business combination under the acquisition method of accounting. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.14%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.7%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.04%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Acquisition&amp;#160;Date(a)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Measurement&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Period&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Adjustments(b)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(as&amp;#160;adjusted)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.14%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Inventories&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.7%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.74%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;32,360&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(3,792&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;28,568&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.14%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.7%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.04%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;39,581&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;39,581&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.14%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Identifiable intangible assets(c)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.7%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.04%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;341,680&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,969&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;343,649&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.14%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.7%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.04%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(1,262&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(1,262&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.14%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total identifiable net assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.7%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.04%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;412,359&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(1,823&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;410,536&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.14%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Goodwill(d)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.7%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.04%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8,141&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,935&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;11,076&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.14%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total fair value of consideration transferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.7%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.74%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;420,500&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,112&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;421,612&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(a)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;As previously reported in the 2011 Form&amp;#160;10-K.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(b)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The measurement period adjustments primarily reflect: (i)&amp;#160;changes in estimated inventory reserves, (ii)&amp;#160;revisions to certain assumptions impacting the fair value of intangible assets; and (iii)&amp;#160;an increase in the total fair value of consideration transferred pursuant to a working capital adjustment provision under the purchase agreement. The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company&amp;#8217;s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(c)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The following table summarizes the amounts and useful lives assigned to identifiable intangible assets:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.75in; WIDTH: 90%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="90%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 35.12%; PADDING-TOP: 0in" valign="bottom" width="35%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.2%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Weighted-&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Useful&amp;#160;Lives&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(Years)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.24%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Acquisition&amp;#160;Date&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.22%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Measurement&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Period&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Adjustments&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.22%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(as&amp;#160;adjusted)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 0.98%; PADDING-TOP: 0in" valign="bottom" width="0%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 35.12%; PADDING-TOP: 0in" valign="bottom" width="35%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Product brands&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.46%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.78%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;292,472&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.78%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,816&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.78%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;294,288&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 0.98%; PADDING-TOP: 0in" valign="bottom" width="0%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 35.12%; PADDING-TOP: 0in" valign="bottom" width="35%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Product rights&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.2%; PADDING-TOP: 0in" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.24%; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;33,857&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.22%; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;227&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.22%; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;34,084&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 0.98%; PADDING-TOP: 0in" valign="bottom" width="0%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 35.12%; PADDING-TOP: 0in" valign="bottom" width="35%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Manufacturing agreement&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.2%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.24%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;15,351&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.22%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(74&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.22%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;15,277&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 0.98%; PADDING-TOP: 0in" valign="bottom" width="0%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 35.12%; PADDING-TOP: 0in" valign="bottom" width="35%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total identifiable intangible assets acquired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.2%; PADDING-TOP: 0in" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.46%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.78%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;341,680&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.78%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,969&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.76%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.78%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;343,649&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 0.98%; PADDING-TOP: 0in" valign="bottom" width="0%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(d)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. The Company expects that $6.4 million of the goodwill will be deductible for tax purposes. The goodwill recorded represents primarily the value of Dermik&amp;#8217;s assembled workforce. The goodwill has been allocated to the Company&amp;#8217;s U.S. Dermatology segment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Ortho Dermatologics&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Description of the Transaction&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On December&amp;#160;12, 2011, the Company acquired assets of the Ortho Dermatologics division of Janssen Pharmaceuticals,&amp;#160;Inc., for a total cash purchase price of approximately $345.2 million. The assets acquired included prescription brands Retin-A Micro&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;, Ertaczo&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;, Renova&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;and Biafine&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Ortho Dermatologics is a leader in the field of dermatology and has developed several products to treat skin disorders and dermatologic conditions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Assets Acquired and Liabilities Assumed&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The transaction has been accounted for as a business combination under the acquisition method of accounting. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Acquisition&amp;#160;Date(a)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Measurement&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Period&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Adjustments(b)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.9%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(as&amp;#160;adjusted)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Inventories&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.72%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6,169&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.58%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.6%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6,169&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;206&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.9%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;206&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Identifiable intangible assets, excluding acquired IPR&amp;amp;D(c)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;333,599&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.9%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;333,599&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Acquired IPR&amp;amp;D(d)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;4,318&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.9%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;4,318&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Deferred tax liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(1,690&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.9%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(1,690&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total identifiable net assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.02%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;342,602&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.9%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;342,602&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Goodwill(e)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3,507&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(915&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.9%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,592&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total fair value of consideration transferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.72%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;346,109&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.58%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(915&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 2.25pt; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.6%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;345,194&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(a)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;As previously reported in the 2011 Form&amp;#160;10-K.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(b)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The measurement period adjustment reflects a decrease in the total fair value of consideration transferred pursuant to a working capital adjustment provision under the purchase agreement. The measurement period adjustment was made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. This adjustment did not have a significant impact on the Company&amp;#8217;s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(c)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The identifiable intangible assets acquired relate to product brands intangible assets with an estimated weighted-average useful life of approximately nine years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(d)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The acquired IPR&amp;amp;D asset relates to the development of the MC5 program, a topical treatment for acne vulgaris. In the second quarter of 2012, the Company terminated the MC5 program and recognized a charge of $4.3 million to write off the related IPR&amp;amp;D asset. This charge was recognized as Acquired in-process research and development in the Company&amp;#8217;s consolidated statements of income (loss).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(e)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. None of the goodwill is expected to be deductible for tax purposes. The goodwill recorded represents primarily the cost savings, operating synergies and other benefits expected to result from combining the operations of Ortho Dermatologics with those of the Company. The goodwill has been allocated to the Company&amp;#8217;s U.S. Dermatology segment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Afexa&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Description of the Transaction&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On October&amp;#160;17, 2011, the Company acquired 73.8% (80,929,921 common shares) of the outstanding common shares of Afexa Life Sciences Inc. (&amp;#8220;Afexa&amp;#8221;) for cash consideration of $67.7 million. The acquisition date fair value of the 26.2% noncontrolling interest in Afexa of $23.8 million was estimated using quoted market prices on such date, for a total fair value of consideration transferred of $91.5 million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;At a special meeting of Afexa shareholders held on December&amp;#160;12, 2011, a subsequent acquisition transaction was approved resulting in the privatization of Afexa and the remaining shareholders receiving C$0.85 per share. Consequently, as of December&amp;#160;31, 2011, the Company owned 100% of Afexa.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Afexa markets several consumer brands, such as Cold-FX&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;, an OTC cold and flu treatment, and Coldsore-FX&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;, a topical OTC cold sore treatment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Assets Acquired and Liabilities Assumed&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The transaction has been accounted for as a business combination under the acquisition method of accounting. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Acquisition&amp;#160;Date(a)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Measurement&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Period&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Adjustments(b)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.9%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(as&amp;#160;adjusted)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.72%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,558&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.58%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.6%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,558&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Accounts receivable(c)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;9,436&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(1,524&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.9%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7,912&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Inventories&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;22,489&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.9%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;22,489&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other current assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;5,406&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.9%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;5,406&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Property and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8,766&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.9%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8,766&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Identifiable intangible assets(d)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;80,580&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(5,850&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.9%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;74,730&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Current liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(18,104&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.9%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(18,104&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Deferred income taxes, net&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 14.02%; PADDING-TOP: 0in" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(20,533&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.88%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,462&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.9%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(19,071&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other non-current liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(1,138&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.9%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(1,138&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total identifiable net assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.02%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="14%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;88,460&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(5,912&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.9%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;82,548&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Goodwill(e)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 14.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="14%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3,070&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.88%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;5,912&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.9%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8,982&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.12%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total fair value of consideration transferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.72%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;91,530&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.58%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.6%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;91,530&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.04%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(a)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;As previously reported in the 2011 Form&amp;#160;10-K.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(b)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The measurement period adjustments primarily reflect: (i)&amp;#160;changes in the estimated fair value of certain intangible assets; (ii)&amp;#160;changes in estimated sales reserves; and (iii)&amp;#160;the tax impact of pre-tax measurement period adjustments. The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company&amp;#8217;s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(c)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Both the fair value and gross contractual amount of trade accounts receivable acquired were $7.9 million, as the Company expects that the amount to be uncollectible is negligible.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(d)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The following table summarizes the amounts and useful lives assigned to identifiable intangible assets:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.75in; WIDTH: 90%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="90%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 34.44%; PADDING-TOP: 0in" valign="bottom" width="34%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Weighted-&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Useful&amp;#160;Lives&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(Years)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Acquisition&amp;#160;Date&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Measurement&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Period&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Adjustments&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Amounts&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Recognized&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(as&amp;#160;adjusted)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.12%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 34.44%; PADDING-TOP: 0in" valign="bottom" width="34%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Product brands&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;11&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.9%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;65,194&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.9%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(5,850&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.9%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;59,344&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.12%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 34.44%; PADDING-TOP: 0in" valign="bottom" width="34%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Patented technology&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13.34%; PADDING-TOP: 0in" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;15,386&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.34%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;15,386&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.12%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 34.44%; PADDING-TOP: 0in" valign="bottom" width="34%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total identifiable intangible assets acquired&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13.34%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;10&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.9%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;80,580&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.9%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(5,850&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 2.25pt; WIDTH: 2.78%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.9%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;74,730&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.12%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(e)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. None of the goodwill is expected to be deductible for tax purposes. The goodwill recorded represents the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;cost savings, operating synergies and other benefits expected to result from combining the operations of Afexa with those of the Company; and&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;intangible assets that do not qualify for separate recognition (for instance, Afexa&amp;#8217;s assembled workforce).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The goodwill has been allocated to the Company&amp;#8217;s Canada and Australia segment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Sanitas&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Description of the Transaction&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On August&amp;#160;19, 2011 (the &amp;#8220;Sanitas Acquisition Date&amp;#8221;), the Company acquired 87.2% of the outstanding shares of AB Sanitas (&amp;#8220;Sanitas&amp;#8221;) for cash consideration of $392.3 million. Prior to the Sanitas Acquisition Date, the Company acquired 1,502,432 shares of Sanitas, which represented approximately 4.8% of the outstanding shares. As a result, as of the Sanitas Acquisition Date, the Company held a controlling financial interest in Sanitas of 92%, or 28,625,025 shares. The acquisition date fair value of the 8% noncontrolling interest in Sanitas of $34.8 million, and the acquisition date fair value of the previously-held 4.8% equity interest of $21.1 million, were estimated using quoted market prices on such date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On September&amp;#160;2, 2011, the Company announced a mandatory non-competitive tender offer (the &amp;#8220;Tender Offer&amp;#8221;) to purchase the remaining outstanding ordinary shares of Sanitas from all public shareholders at &amp;#8364;10.06 per share. The Tender Offer closed on September&amp;#160;15, 2011, on which date the Company purchased an additional 1,968,631 shares (6.4% of the outstanding shares of Sanitas) for approximately $27.4 million. As a result of this purchase, the Company owned 30,593,656 shares or approximately 98.4% of Sanitas as of September&amp;#160;15, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On September&amp;#160;22, 2011, the Company received approval from the Securities Commission of the Republic of Lithuania to conduct the mandatory tender offer through squeeze out procedures (the &amp;#8220;Squeeze Out&amp;#8221;) at a price per one ordinary share of Sanitas equal to &amp;#8364;10.06, which required that all minority shareholders sell to the Company the ordinary shares of Sanitas owned by them (512,264 ordinary shares, or 1.6% of Sanitas).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;As the Company maintained a controlling financial interest in Sanitas during the Tender Offer, the additional ownership interest of 6.4% acquired in Sanitas was accounted for as an equity transaction between owners. The noncontrolling interest in Sanitas of approximately 1.6% to be acquired through the Squeeze Out procedures was classified as a liability in the Company&amp;#8217;s consolidated balance sheet as it was mandatorily redeemable. As of September&amp;#160;30, 2012, the amount due to Sanitas shareholders of $2.4 million was included in Accrued liabilities and other current liabilities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Sanitas has a broad branded generics product portfolio consisting of 390 products in nine countries throughout Central and Eastern Europe, primarily Poland, Russia and Lithuania. Sanitas has in-house development capabilities in dermatology, hospital injectables and ophthalmology, and a pipeline of internally developed and acquired dossiers.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Assets Acquired and Liabilities Assumed&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The transaction has been accounted for as a business combination under the acquisition method of accounting. The Company has not recognized any additional measurement period adjustments to the amounts previously reported in the 2011 Form&amp;#160;10-K. The amount of goodwill of $204.8 million has been allocated to the Company&amp;#8217;s Emerging Markets segment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;PharmaSwiss&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Description of the Transaction&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On March&amp;#160;10, 2011, the Company acquired all of the issued and outstanding stock of PharmaSwiss S.A. (&amp;#8220;PharmaSwiss&amp;#8221;), a privately-owned branded generics and OTC pharmaceutical company based in Zug, Switzerland. As of the acquisition date, the total consideration transferred to effect the acquisition of PharmaSwiss comprised of cash paid of $491.2 million (&amp;#8364;353.1 million) and the rights to contingent consideration payments of up to $41.7 million (&amp;#8364;30.0 million) if certain net sales milestones of PharmaSwiss were achieved for the 2011 calendar year. The fair value of the contingent payments was determined to be $27.5 million as of the acquisition date. In May&amp;#160;2012, the Company made a contingent consideration payment of $12.4 million (&amp;#8364;10.0 million) based on the net sales results for the 2011 calendar year. There are no remaining contingent consideration payments under this arrangement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In connection with the transaction, in February&amp;#160;2011, the Company entered into foreign currency forward-exchange contracts to buy &amp;#8364;130.0 million, which were settled on March&amp;#160;9, 2011. The Company recorded a $5.1 million gain on the settlement of these contracts, which was partially offset by a foreign exchange loss of $2.4 million recognized on the remaining &amp;#8364;220.0 million bought to finance the transaction. The net foreign exchange gain of $2.7 million was recognized in Foreign exchange and other in the consolidated statement of income (loss) in the three-month period ended March&amp;#160;31, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;PharmaSwiss is an existing partner to several large pharmaceutical and biotech companies offering regional expertise in such functions as regulatory, compliance, sales, marketing and distribution, in addition to developing its own product portfolio. Through its business operations, PharmaSwiss offers a broad product portfolio in seven therapeutic areas and operations in 19 countries throughout Central and Eastern Europe, including Serbia, Hungary, the Czech Republic and Poland, as well as in Greece and Israel.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Assets Acquired and Liabilities Assumed&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The transaction has been accounted for as a business combination under the acquisition method of accounting. The Company has not recognized any additional measurement period adjustments to the amounts previously reported in the 2011 Form&amp;#160;10-K. The amount of goodwill of $159.7 million has been allocated to the Company&amp;#8217;s Emerging Markets segment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Pro Forma Impact of Business Combinations&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The following table presents unaudited pro forma consolidated results of operations for the three-month and nine-month periods ended September&amp;#160;30, 2012 and 2011, as if the J&amp;amp;J North America, QLT, OraPharma, University Medical, Atlantis, Gerot Lannach and Probiotica acquisitions had occurred as of January&amp;#160;1, 2011 and the PharmaSwiss, Sanitas, Ortho Dermatologics, iNova and Afexa acquisitions had occurred as of January&amp;#160;1, 2010. The unaudited pro forma information does not include the license agreement entered into in June&amp;#160;2011 to acquire the rights to Elidel&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;and Xerese&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;, as the impact is immaterial to these pro forma results and it was impracticable to obtain the necessary historical information as discrete financial statements for these product lines were not prepared. In addition, the unaudited pro forma information does not include the Dermik acquisition, as it was impracticable to obtain the necessary historical information as discrete financial statements were not prepared.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.84%; PADDING-TOP: 0in" valign="bottom" width="36%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 28.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="28%" colspan="5"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Three Months Ended&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;September 30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 28.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="28%" colspan="5"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Nine Months Ended&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;September 30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.84%; PADDING-TOP: 0in" valign="bottom" width="36%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2011&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2011&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.84%; PADDING-TOP: 0in" valign="bottom" width="36%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Revenues&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.38%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.48%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;901,630&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.38%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.48%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;805,663&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.38%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.48%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,687,041&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.38%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.48%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,433,477&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.84%; PADDING-TOP: 0in" valign="bottom" width="36%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Net income&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;13,159&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;18,292&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;9,783&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;70,838&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 36.84%; PADDING-TOP: 0in" valign="bottom" width="36%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Basic earnings per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.48%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.04&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.48%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.06&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.48%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.03&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.48%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.23&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 36.84%; PADDING-TOP: 0in" valign="bottom" width="36%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Diluted earnings per share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.48%; PADDING-TOP: 0in" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.04&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.48%; PADDING-TOP: 0in" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.06&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.48%; PADDING-TOP: 0in" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.03&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.38%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.48%; PADDING-TOP: 0in" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.22&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The unaudited pro forma consolidated results of operations were prepared using the acquisition method of accounting and are based on the historical financial information of the Company, J&amp;amp;J North America, QLT, OraPharma, University Medical, Atlantis, Gerot Lannach, Probiotica, PharmaSwiss, Sanitas, Ortho Dermatologics, iNova and Afexa. Except to the extent realized in the three-month and nine-month periods ended September&amp;#160;30, 2012, the unaudited pro forma information does not reflect any cost savings, operating synergies and other benefits that the Company may achieve as a result of these acquisitions, or the costs necessary to achieve these cost savings, operating synergies and other benefits. In addition, except to the extent recognized in the three-month and nine-month periods ended September&amp;#160;30, 2012, the unaudited pro forma information does not reflect the costs to integrate the operations of the Company with those of J&amp;amp;J North America, QLT, OraPharma, University Medical, Atlantis, Gerot Lannach, Probiotica, PharmaSwiss, Sanitas, Ortho Dermatologics, iNova and Afexa.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The unaudited pro forma information is not necessarily indicative of what the Company&amp;#8217;s consolidated results of operations actually would have been had the J&amp;amp;J North America, QLT, OraPharma, University Medical, Atlantis, Gerot Lannach and Probiotica acquisitions and the PharmaSwiss, Sanitas, Ortho Dermatologics, iNova and Afexa acquisitions been completed on January&amp;#160;1, 2011 and January&amp;#160;1, 2010, respectively. In addition, the unaudited pro forma information does not purport to project the future results of operations of the Company. The unaudited pro forma information reflects primarily adjustments consistent with the unaudited pro forma information related to the following unaudited pro forma adjustments related to these acquisitions:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;elimination of J&amp;amp;J North America&amp;#8217;s, QLT&amp;#8217;s, OraPharma&amp;#8217;s, University Medical&amp;#8217;s, Atlantis&amp;#8217;, Gerot Lannach&amp;#8217;s, Probiotica&amp;#8217;s, PharmaSwiss&amp;#8217;, Sanitas&amp;#8217;, Ortho Dermatologics&amp;#8217;, iNova&amp;#8217;s and Afexa&amp;#8217;s historical intangible asset amortization expense;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;additional amortization expense related to the provisional fair value of identifiable intangible assets acquired;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;additional depreciation expense related to fair value adjustment to property, plant and equipment acquired;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;additional interest expense associated with the financing obtained by the Company in connection with the various acquisitions;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;the exclusion from pro forma earnings in the nine-month period ended September&amp;#160;30, 2012 of the acquisition accounting adjustments on QLT&amp;#8217;s, iNova&amp;#8217;s, Ortho Dermatologics&amp;#8217;, Afexa&amp;#8217;s, Probiotica&amp;#8217;s, OraPharma&amp;#8217;s, University Medical&amp;#8217;s, and Atlantis&amp;#8217; inventories that were sold subsequent to the acquisition date of $31.1&lt;b&gt; &lt;/b&gt;million, in the aggregate, and the exclusion of $16.7&lt;b&gt; &lt;/b&gt;million of acquisition-related costs, in the aggregate, incurred primarily for the J&amp;amp;J North America, QLT, OraPharma, University Medical, Atlantis, Gerot Lannach, and Probiotica acquisitions in the nine-month period ended September&amp;#160;30, 2012, and the inclusion of those amounts in pro forma earnings for the applicable comparative periods; and&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;the exclusion from pro forma earnings in the three-month period ended September&amp;#160;30, 2012 of the acquisition accounting adjustments on QLT&amp;#8217;s, iNova&amp;#8217;s, Ortho Dermatologics&amp;#8217;, Afexa&amp;#8217;s, Probiotica&amp;#8217;s, OraPharma&amp;#8217;s, University Medical&amp;#8217;s, and Atlantis&amp;#8217; inventories that were sold subsequent to the acquisition date of $2.9&lt;b&gt; &lt;/b&gt;million, and the inclusion of those amounts in pro forma earnings for the applicable comparative periods.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The pro forma earnings also exclude amortization of inventory step-up that arose from the Merger that was recognized in the nine-month period ended September&amp;#160;30, 2011. Such amounts were included in the applicable comparative period for purposes of pro forma financial information.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In addition, all of the above adjustments were adjusted for the applicable tax impact.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:BusinessCombinationDisclosureTextBlock>
  <vrx:AcquisitionsDispositionsDisclosuresTextBlock id="Tag115" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;4.&lt;/font&gt;&lt;/b&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;ACQUISITIONS AND DISPOSITIONS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Divestitures of IDP-111 and 5-FU&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In connection with the acquisition of Dermik, the Company was required by the FTC to divest 1% clindamycin and 5% benzoyl peroxide gel (&amp;#8220;IDP-111&amp;#8221;), a generic version of BenzaClin&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;, and 5% fluorouracil cream (&amp;#8220;5-FU&amp;#8221;), an authorized generic of&amp;#160;Efudex&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On February&amp;#160;3, 2012, the Company sold the IDP-111 and 5-FU products. In the fourth quarter of 2011, the Company recognized $7.9 million and $19.8 million of impairment charges related to the write-down of the carrying values of the IDP-111 and 5-FU intangible assets, respectively, to their estimated fair values, less costs to sell. The adjusted carrying values of $54.4 million and $14.8 million for IDP-111 and 5-FU, respectively, were classified as Assets held for sale on the consolidated balance sheet as of December&amp;#160;31, 2011 and were included within the U.S.&amp;#160;Dermatology reporting segment. IDP-111 and 5-FU were considered non-core products with respect to the Company&amp;#8217;s business strategy, which contemplates, on an ongoing basis, the selective purchase and sale of products and assets with a focus on core geographies and therapeutic classes. The Company, therefore, considers the sale or the out-license of non-core products to be part of its ongoing major and central operations. Accordingly, proceeds on the sale of non-core products are recognized as alliance revenue, with the associated costs, including the carrying amount of related assets, recorded as cost of alliance revenue. In connection with the sale of the IDP-111 and 5-FU, the Company recognized $66.3 million of cash proceeds as alliance revenue in the first quarter of 2012 and expensed the carrying amounts of the IDP-111 and 5-FU assets of $69.2 million, in the aggregate, as cost of alliance revenue. The cash proceeds from this transaction are classified within investing activities in the consolidated statements of cash&amp;#160;flows.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cloderm&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On March&amp;#160;31, 2011, the Company out-licensed the product rights to Cloderm&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;Cream, 0.1%, in the U.S.&amp;#160;to Promius Pharma&amp;#160;LLC, an affiliate of Dr.&amp;#160;Reddy&amp;#8217;s Laboratories, in exchange for a $36.0 million up-front payment, which was received in early April&amp;#160;2011, and future royalty payments. The Cloderm&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;product rights intangible asset was recorded at a fair value of $31.8 million as of the Merger Date, and had a remaining unamortized carrying value of $30.7 million at March&amp;#160;31, 2011. Cloderm&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;was considered a non-core product with respect to the Company&amp;#8217;s business strategy. Accordingly, the Company recognized the up-front payment as alliance revenue in the first quarter of 2011 and expensed the carrying amount of the Cloderm&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;intangible assets as cost of alliance revenue. The cash proceeds from this transaction are classified within investing activities in the consolidated statements of cash flows. The Company recognizes the royalty payments as alliance revenue as they are&amp;#160;earned.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Zovirax&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On February&amp;#160;22, 2011 and March&amp;#160;25, 2011, the Company acquired the U.S. and Canadian rights, respectively, to non-ophthalmic topical formulations of Zovirax&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;from GlaxoSmithKline (&amp;#8220;GSK&amp;#8221;). Pursuant to the terms of the asset purchase agreements, the Company paid GSK an aggregate amount of $300.0 million in cash for both the U.S. and Canadian rights. The Company had been marketing Zovirax&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;in the U.S.&amp;#160;since January&amp;#160;1, 2002, under a 20-year exclusive distribution agreement with GSK, which distribution agreement terminated following the closing of the U.S.&amp;#160;transaction. The Company has entered into new supply agreements and new trademark license agreements with GSK with respect to the U.S. and Canadian territories.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;This acquisition was accounted for as a purchase of identifiable intangible assets. Accordingly, the purchase price (including costs of acquisition) was allocated to the product brand intangible asset, with an estimated weighted-average useful life of 11 years. In addition, the Company reclassified the $91.4 million unamortized carrying amount of the original exclusive distribution agreement from product rights to the product brand intangible asset, to be amortized over the same 11-year estimated useful&amp;#160;life.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</vrx:AcquisitionsDispositionsDisclosuresTextBlock>
  <vrx:CollaborationAgreementDisclosureTextBlock id="Tag116" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;5.&lt;/font&gt;&lt;/b&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;b&gt;COLLABORATION AGREEMENT&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In October&amp;#160;2008, Valeant closed the worldwide License and Collaboration Agreement (the&amp;#160;&amp;#8220;Collaboration Agreement&amp;#8221;) with GSK to develop and commercialize a first-in-class neuronal potassium channel opener for treatment of adult epilepsy patients with refractory partial onset seizures and its backup compounds, with a generic name of ezogabine in the U.S. and retigabine in all other countries. Pursuant to the terms of the Collaboration Agreement, Valeant granted co-development rights and worldwide commercialization rights to&amp;#160;GSK.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In March&amp;#160;2011, the European Commission granted marketing authorization for Trobalt&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;(retigabine) as an adjunctive treatment of partial onset seizures, with or without secondary generalization in adults aged 18&amp;#160;years and above with epilepsy. In June&amp;#160;2011, the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) approved the New Drug Application for Potiga&amp;#8482; (ezogabine) tablets as adjunctive treatment of partial-onset seizures in patients aged 18&amp;#160;years and older; however, the FDA recommended that ezogabine be scheduled as a controlled substance under the Controlled Substances Act prior to the marketing or launch of Potiga&amp;#8482;. In December&amp;#160;2011, ezogabine/retigabine received scheduling as a controlled substance, which triggered the commencement of amortization.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In connection with the first sale of Potiga&amp;#8482; in the U.S. (which occurred in April&amp;#160;2012), GSK paid the Company a $45.0 million milestone payment, and the Company will share up to 50% of the net profits from the sale of Potiga&amp;#8482;. In addition, in connection with the first sale of Trobalt&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;by GSK in the European Union (which occurred in May&amp;#160;2011), GSK paid the Company a $40.0 million milestone payment and will pay up to a 20% royalty on net sales of the product. As substantive uncertainty existed at the inception of the Collaboration Agreement as to whether the milestones would be achieved because of the uncertainty involved with obtaining regulatory approval, no amounts were previously recognized for these potential milestone payments. The milestone payments (1)&amp;#160;relate solely to past performance of the Company, (2)&amp;#160;are reasonable relative to the other deliverables and payment terms within the Collaboration Agreement, and (3)&amp;#160;are commensurate with the Company&amp;#8217;s efforts in collaboration with GSK to achieve the milestone events and the increase in value of ezogabine/retigabine. Accordingly, the milestones are considered substantive, and the milestone payments are being recognized by the Company as alliance and royalty revenue upon achievement. In the second quarter of 2012 and 2011, the Company recorded $45.0 million and $40.0 million of milestone payments from GSK in connection with the launches of Potiga&amp;#8482; and Trobalt&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</vrx:CollaborationAgreementDisclosureTextBlock>
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock id="Tag117" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6.&lt;/font&gt;&lt;/b&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt; &lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;RESTRUCTURING,&amp;#160;INTEGRATION AND OTHER COSTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company has completed measures to integrate the operations of Biovail and Valeant, capture operating synergies and generate cost savings across the Company. In connection with these cost-rationalization and integration initiatives, the Company has incurred costs including: employee termination costs (including related share-based payments) payable to approximately 500&amp;#160;employees of Biovail and Valeant who were terminated as a result of the Merger; IPR&amp;amp;D termination costs related to the transfer to other parties of product-development programs that did not align with the Company&amp;#8217;s research and development model; costs to consolidate or close facilities and relocate employees, asset impairments charges to write down property, plant and equipment to fair value; and contract termination and lease cancellation costs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The following table summarizes the major components of costs incurred in connection with these initiatives through September&amp;#160;30, 2012:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 24.8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="24%" colspan="5"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Employee Termination Costs&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.44%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;IPR&amp;amp;D&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.54%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Contract&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Termination,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 9.4%; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Severance&amp;#160;and&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Related&amp;#160;Benefits&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2.1%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.2%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Share-Based&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Compensation&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Termination&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Costs&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Facility&amp;#160;Closure&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;and&amp;#160;Other&amp;#160;Costs&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Balance, January&amp;#160;1, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.9%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="9%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.14%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="9%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.24%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.1%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Costs incurred and charged to expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.5%; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;58,727&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.2%; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;49,482&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.44%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;13,750&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.54%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;12,862&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 9.4%; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;134,821&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Cash payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.5%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(33,938&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.2%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.44%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(13,750&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.54%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(8,755&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 9.4%; PADDING-TOP: 0in" valign="bottom" width="9%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(56,443&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Non-cash adjustments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.2%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(49,482&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(2,437&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(51,919&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Balance, December&amp;#160;31, 2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;24,789&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;1,670&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="9%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;26,459&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Costs incurred and charged to expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.5%; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;14,548&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.2%; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;3,455&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.44%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.54%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;28,938&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 9.4%; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;46,941&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Cash payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.5%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(38,168&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.2%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(2,033&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.44%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.54%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(15,381&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 9.4%; PADDING-TOP: 0in" valign="bottom" width="9%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(55,582&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Non-cash adjustments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;989&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.2%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(741&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(4,913&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(4,665&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Balance, December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2,158&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;681&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;10,314&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="9%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;13,153&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Costs incurred and charged to expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.5%; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;1,586&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.2%; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.44%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.54%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;12,334&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 9.4%; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;13,920&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Cash payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.5%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(3,288&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.2%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.44%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.54%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(22,572&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 9.4%; PADDING-TOP: 0in" valign="bottom" width="9%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(25,860&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Non-cash adjustments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;442&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.2%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(681&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;378&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;139&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Balance, March&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;898&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;454&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="9%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;1,352&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Costs incurred and charged to expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.5%; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.2%; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.44%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.54%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 9.4%; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Cash payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.5%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(409&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.2%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.44%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.54%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(14&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 9.4%; PADDING-TOP: 0in" valign="bottom" width="9%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(423&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Non-cash adjustments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.2%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(193&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(199&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Balance, June&amp;#160;30, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;483&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.44%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;247&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.4%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="9%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;730&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Costs incurred and charged to expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.5%; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.2%; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.44%; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.54%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;252&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 9.4%; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;252&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Cash payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.5%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(80&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.2%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.44%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.54%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(81&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 9.4%; PADDING-TOP: 0in" valign="bottom" width="9%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(161&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Non-cash adjustments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(134&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.2%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="11%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.44%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.54%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;15&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.4%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(119&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 33.38%; PADDING-TOP: 0in" valign="bottom" width="33%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Balance, September&amp;#160;30, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.2%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;269&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.1%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.9%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="9%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 9.14%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="9%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 11.24%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;433&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.08%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.1%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="8%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;702&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Facility closure costs incurred in the nine-month period ended September&amp;#160;30, 2012 primarily included an incremental $10.2 million charge for the remaining operating lease obligations related to our vacated Mississauga, Ontario corporate office facility.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In addition to costs associated with the Company&amp;#8217;s Merger-related initiatives, in the nine-month period ended September&amp;#160;30, 2012, the Company incurred an additional $121.0&lt;b&gt; &lt;/b&gt;million of other restructuring, integration-related and other costs, including (i)&amp;#160;$46.6 million of integration consulting, duplicate labor, transition service, and other, (ii)&amp;#160;$44.8 million of severance costs, (iii)&amp;#160;$14.9 million of facility closure costs and (iv)&amp;#160;$14.7 million of other costs, including non-personnel manufacturing integration costs. The Company also made payments of $107.7 million during the nine-month period ended September&amp;#160;30, 2012. These costs were primarily related to the acquisitions of Dermik, iNova, Sanitas, Ortho Dermatologics, OraPharma, Afexa, PharmaSwiss, and a U.S. restructuring focused primarily on a reduction in the prescription dermatology field force, the global consolidation of the Company&amp;#8217;s manufacturing facilities, and systems integration initiatives.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="Tag118" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',times,serif"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7.&lt;/font&gt;&lt;/b&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;FAIR VALUE MEASUREMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&lt;strong&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/strong&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The following fair value hierarchy table presents the components of the Company&amp;#8217;s financial assets and liabilities measured at fair value as of September&amp;#160;30, 2012 and December&amp;#160;31, 2011:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 38%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="38%" colspan="11"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;As&amp;#160;of&amp;#160;September&amp;#160;30,&amp;#160;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 37.98%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="37%" colspan="11"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2011&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Carrying&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Value&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Quoted&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Prices&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Markets&amp;#160;for&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Identical&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Assets&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Significant&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Other&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Observable&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Inputs&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Significant&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Unobservable&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Inputs&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Carrying&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Value&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Quoted&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Prices&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Markets&amp;#160;for&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Identical&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Assets&lt;br /&gt;
(Level&amp;#160;1)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Significant&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Other&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Observable&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Inputs&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Significant&lt;br /&gt;
Unobservable&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Inputs&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.02%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Money market funds&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.32%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;8,047&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;8,047&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;27,711&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;27,711&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Available-for-sale equity securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 8.02%; PADDING-TOP: 0in" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;3,364&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;3,364&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Available-for-sale debt securities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8.02%; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 30pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Corporate bonds&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2,974&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2,974&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Total financial assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.32%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;8,047&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;8,047&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;34,049&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;34,049&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.02%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.32%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;8,047&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;8,047&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;27,711&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;27,711&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;6,338&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;6,338&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Total financial assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.32%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;8,047&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;8,047&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;34,049&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;34,049&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8.02%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Acquisition-related contingent consideration&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.32%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(505,235&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(505,235&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(420,084&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 6.7%; PADDING-TOP: 0in" valign="bottom" width="6%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 8%; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(420,084&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Fair value measurements are estimated based on valuation techniques and inputs categorized as&amp;#160;follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; Quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; Observable inputs other than Level&amp;#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&amp;#160;and&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&amp;#160;estimation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&amp;#160;instrument.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;There were no transfers between Level&amp;#160;1 and Level&amp;#160;2 during the nine-month period ended September&amp;#160;30, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level&amp;#160;3)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The fair value measurement of contingent consideration obligations arising from business combinations is determined using unobservable (Level&amp;#160;3) inputs. These inputs include (i)&amp;#160;the estimated amount and timing of projected cash flows; (ii)&amp;#160;the probability of the achievement of the factor(s)&amp;#160;on which the contingency is based; and (iii)&amp;#160;the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases (decreases) in any of those inputs in isolation could result in a significantly lower (higher) fair value measurement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&amp;#160;3) for the nine-month period ended September&amp;#160;30, 2012:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Balance,&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;January&amp;#160;1,&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Issuances(a)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Payments(b)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Net&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;unrealized&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Loss(&amp;#160;(c)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Foreign&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Exchange(d)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Transfers&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Into&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Transfers&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Out&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Balance,&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;September&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;30,&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Acquisition-related contingent consideration&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(420,084&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(143,285&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;81,294&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(23,198&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;38&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(505,235&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="132"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="13"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="49"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="13"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="9"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="49"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="13"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="10"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="51"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="13"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="46"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="13"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="10"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="51"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="13"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="46"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="13"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="46"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="13"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="49"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="6"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(a)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Relates primarily to the OraPharma, Gerot Lannach, QLT, Atlantis and University Medical acquisitions as described above in note&amp;#160;3.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(b)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Relates primarily to payments of acquisition-related contingent consideration related to the Elidel&amp;#174;/Xerese&amp;#174; license agreement entered into in June&amp;#160;2011 and the PharmaSwiss acquisition.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(c)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Recognized as Acquisition-related contingent consideration in the consolidated statements of income (loss). The balance is primarily driven by fair value adjustments to reflect accretion for the time value of money of $19.5 million related to the Elidel&amp;#174;/Xerese&amp;#174; license agreement and $6.2 million related to the iNova acquisition described above in note&amp;#160;3. These charges were partially offset by a gain of $4.4 million related to a shift in timing which impacted the revenue assumptions associated with potential milestone payments for the A007 (Lacrisert&amp;#174;) development program.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(d)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Included in Foreign exchange and other in the consolidated statements of income (loss).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;There were no significant assets or liabilities that were re-measured at fair value on a non-recurring basis subsequent to initial recognition in the nine-month period ended September&amp;#160;30, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FinancialInstrumentsDisclosureTextBlock id="Tag119" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8.&lt;/font&gt;&lt;/b&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The following table summarizes the estimated fair values of the Company&amp;#8217;s financial instruments as of September&amp;#160;30, 2012 and December&amp;#160;31, 2011:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.36%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 26.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="26%" colspan="5"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;As&amp;#160;of&amp;#160;September&amp;#160;30,&amp;#160;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 26.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="26%" colspan="5"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2011&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Carrying&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Value&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Fair&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Value&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Carrying&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Value&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Fair&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Value&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8,047&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8,047&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;27,711&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;27,711&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6,338&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6,338&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Long-term debt (as described in note 11)(a)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(7,630,246&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(8,125,088&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(6,651,011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(6,732,568&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="286"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="17"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="9"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="75"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="17"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="9"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="75"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="17"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="9"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="75"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="17"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="9"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="75"&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: medium none" width="7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(a)&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Fair value measurement of long-term debt was estimated using the quoted market prices for the same or similar issues and other pertinent information available to management.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The following table summarizes the Company&amp;#8217;s marketable securities by major security type as of September&amp;#160;30, 2012 and December&amp;#160;31, 2011:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 38%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="38%" colspan="11"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;As&amp;#160;of&amp;#160;September&amp;#160;30,&amp;#160;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 38%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="38%" colspan="11"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2011&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="black" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Cost&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="black" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Fair&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="18%" bgcolor="black" colspan="5"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Gross&amp;#160;Unrealized&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="black" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Cost&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="8%" bgcolor="black" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Fair&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 2%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="18%" bgcolor="black" colspan="5"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Gross&amp;#160;Unrealized&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="black" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Basis&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="black" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Value&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="black" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Gains&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="black" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Losses&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="black" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Basis&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="black" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Value&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="black" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Gains&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 8%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="8%" bgcolor="black" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Losses&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: white; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="black"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 19%; PADDING-TOP: 0in" valign="bottom" width="19%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Corporate bonds&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,983&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,974&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 6.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="6%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&g